[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 79 of about 79
1. Rivera-Arkoncel ML, Pacquing-Songco D, Lantion-Ang FL: Virilising ovarian tumour in a woman with an adrenal nodule. BMJ Case Rep; 2010;2010
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Virilising ovarian tumour in a woman with an adrenal nodule.
  • Androblastomas of the ovary comprise less than 0.5% of all ovarian tumours.
  • Pure Leydig cell tumours are very rare and almost always show secretion of male sex hormones.
  • A low dose dexamethasone suppression test suggested an ovarian source.
  • Doppler transvaginal ultrasound revealed a solid lobulated structure in the right ovary.
  • The patient underwent surgery and histopathology showed a Leydig cell tumour, hilar type.
  • Specific clinical and biochemical investigation of androgen secreting neoplasms is very important for correct diagnosis of these rare tumours.
  • [MeSH-major] Adrenal Gland Neoplasms / diagnosis. Ovarian Neoplasms / diagnosis. Sertoli-Leydig Cell Tumor / diagnosis

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 2002 Jul;87(7):3074-7 [12107203.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jun;88(6):2634-43 [12788867.001]
  • [Cites] Endocr Pract. 2001 Mar-Apr;7(2):120-34 [12940239.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Feb;89(2):453-62 [14764747.001]
  • [Cites] Cancer. 1981 Jul 1;48(1):187-97 [7237384.001]
  • [Cites] Gynecol Endocrinol. 2005 Oct;21(4):238-41 [16316848.001]
  • [Cites] N Engl J Med. 2005 Dec 15;353(24):2578-88 [16354894.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jan;91(1):2-6 [16263820.001]
  • (PMID = 22802276.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] Androblastoma of ovary
  • [Other-IDs] NLM/ PMC3029143
  •  go-up   go-down


2. Alam K, Maheshwari V, Rashid S, Bhargava S: Bilateral Sertoli-Leydig cell tumor of the ovary: a rare case report. Indian J Pathol Microbiol; 2009 Jan-Mar;52(1):97-9
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral Sertoli-Leydig cell tumor of the ovary: a rare case report.
  • Sertoli leydig cell tumors also known as arrhenoblastoma, are a rare member of the sex cord-stromal tumor group of ovarian and testicular cancers, comprising less than 1% of all ovarian tumors, which occur in young adults and are almost always unilateral.
  • We hereby report a case of a 17-year-old female presenting with a short history of irregular menses and an abdominal lump, which was histologically proven to be a bilateral sertoli leydig cell tumor of the ovary, an exceptionally rare entity in itself.
  • [MeSH-major] Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / pathology. Ovary / pathology. Sertoli-Leydig Cell Tumor / diagnosis. Sertoli-Leydig Cell Tumor / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19136796.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


3. Demidov VN, Lipatenkova J, Vikhareva O, Van Holsbeke C, Timmerman D, Valentin L: Imaging of gynecological disease (2): clinical and ultrasound characteristics of Sertoli cell tumors, Sertoli-Leydig cell tumors and Leydig cell tumors. Ultrasound Obstet Gynecol; 2008 Jan;31(1):85-91
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging of gynecological disease (2): clinical and ultrasound characteristics of Sertoli cell tumors, Sertoli-Leydig cell tumors and Leydig cell tumors.
  • OBJECTIVE: To describe the clinical history and ultrasound findings in women with ovarian Sertoli cell, Sertoli-Leydig cell and Leydig cell tumors.
  • METHODS: Women with a histological diagnosis of Sertoli cell tumor, Sertoli-Leydig cell tumor or Leydig cell tumor who had undergone preoperative ultrasound examination were identified from the databases of each of three participating ultrasound centers.
  • The tumors were characterized on the basis of ultrasound images, ultrasound reports and research protocols (when applicable) using the terms and definitions published by the International Ovarian Tumor Analysis (IOTA) group.
  • RESULTS: Of 22 patients identified, 15 had Sertoli-Leydig cell tumors, two had Sertoli cell tumors and five had Leydig cell tumors.
  • Twenty-two (96%) of 23 tumors (one woman had bilateral tumors) contained a solid component; 16 (70%) were purely solid.
  • Pattern recognition showed that the Leydig cell tumors were small solid tumors (four of five had a largest diameter of 1-3 cm) and the two Sertoli cell tumors were somewhat larger solid tumors (4 cm and 7 cm); the Sertoli-Leydig cell tumors were either small (3-4 cm) or medium-sized (6-7 cm) solid tumors, or multilocular solid tumors of any size (3-18 cm) with purely solid areas mixed with areas of innumerable closely packed small cyst locules.
  • CONCLUSIONS: On the basis of endocrine symptoms, the woman's age and ultrasound findings, it should be possible to suggest a correct preoperative diagnosis of Sertoli cell, Sertoli-Leydig cell or Leydig cell tumors in many cases.
  • [MeSH-major] Ovarian Neoplasms / ultrasonography. Sertoli-Leydig Cell Tumor / ultrasonography
  • [MeSH-minor] Adolescent. Adult. Biomarkers, Tumor / metabolism. Cell Differentiation / physiology. Female. Humans. Middle Aged. Pattern Recognition, Automated / methods. Prognosis

  • Genetic Alliance. consumer health - Sertoli-leydig cell tumors.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 ISUOG. Published by John Wiley & Sons, Ltd.
  • (PMID = 18098335.001).
  • [ISSN] 0960-7692
  • [Journal-full-title] Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
  • [ISO-abbreviation] Ultrasound Obstet Gynecol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


Advertisement
4. Trabelsi A, Ben Abdelkarim S, Hadfi M, Fatnaci R, Stita W, Sriha B, Korbi S: Primary mesenteric sertoli-leydig cell tumor: a case report and review of the literature. J Oncol; 2008;2008:619637

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary mesenteric sertoli-leydig cell tumor: a case report and review of the literature.
  • The occurrence of primary sex cord-stromal tumors at extraovarian sites is exceedingly rare.
  • We report a new case of Sertoli-Leydig cell tumor in the mesentery of a 78-year-old woman who presented with occlusive syndrome and reviewed the previously reported cases of extraovarian sex cord-stromal tumors in the English literature.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Indian Med Assoc. 1963 Sep 1;41:254-7 [14063351.001]
  • [Cites] Gynecol Oncol. 1999 Jul;74(1):123-7 [10385563.001]
  • [Cites] Int J Gynecol Pathol. 1997 Apr;16(2):180-5 [9100075.001]
  • [Cites] Am J Clin Pathol. 1991 Aug;96(2):259-62 [1862780.001]
  • [Cites] Physiol Rev. 1986 Jan;66(1):71-117 [3511481.001]
  • [Cites] Yonsei Med J. 2001 Jun;42(3):360-3 [11456406.001]
  • [Cites] Gynecol Oncol. 1988 May;30(1):71-5 [3366395.001]
  • [Cites] Diagn Gynecol Obstet. 1980 Spring;2(1):51-4 [6258889.001]
  • [Cites] Cancer. 1973 Feb;31(2):474-7 [4687888.001]
  • [Cites] Gac Med Mex. 2003 Nov-Dec;139(6):611-6 [14723057.001]
  • [Cites] Acta Obstet Gynecol Scand. 1987;66(8):725-7 [2834911.001]
  • (PMID = 19266086.001).
  • [ISSN] 1687-8450
  • [Journal-full-title] Journal of oncology
  • [ISO-abbreviation] J Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2648635
  •  go-up   go-down


5. Wakui S, Muto T, Kobayashi Y, Ishida K, Nakano M, Takahashi H, Suzuki Y, Furusato M, Hano H: Sertoli-Leydig cell tumor of the testis in a Sprague-Dawley rat. J Am Assoc Lab Anim Sci; 2008 Nov;47(6):67-70
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sertoli-Leydig cell tumor of the testis in a Sprague-Dawley rat.
  • A rare intratubular gonadal stromal tumor was present in the testis of a 7-wk-old male Sprague-Dawley rat.
  • The tumor comprised an intratubular mixture of 2 types of tumor cells with intercellular junctions: the predominant tumor cells were consistent with a Sertoli cell origin, and cells comprising the minor population were situated on basolateral side of the tubuli, consistent with a Leydig cell origin.
  • The neoplastic Sertoli cells had large pleomorphic nuclei and clear cytoplasm with many tubulovesicular cristae and free ribosomes, whereas the neoplastic Leydig cells showed relatively small pleomorphic nuclei, dark cytoplasm with rich smooth endoplasmic reticulum, numerous mitochondria, and lipid droplets.
  • The presence of a thick or multilayered basement membrane was confirmed except in tumor-infiltrative lesions.
  • The present case was considered to be a testicular mixed tubular Sertoli-Leydig cell tumor in a Sprague-Dawley rat.
  • [MeSH-major] Rodent Diseases / pathology. Sertoli-Leydig Cell Tumor / veterinary. Testicular Neoplasms / veterinary
  • [MeSH-minor] Animals. Cell Nucleus / ultrastructure. Cytoplasm / ultrastructure. Male. Microscopy, Electron / veterinary. Rats. Rats, Sprague-Dawley

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arkh Patol. 1973;35(1):66-72 [4690837.001]
  • [Cites] J Comp Pathol. 1983 Apr;93(2):339-42 [6863616.001]
  • [Cites] Endocrinology. 1984 Aug;115(2):550-5 [6146510.001]
  • [Cites] Int Rev Cytol. 1987;109:89-112 [3323108.001]
  • [Cites] Vet Pathol. 1988 Mar;25(2):163-6 [2834860.001]
  • [Cites] Differentiation. 1989 Jun;40(3):198-206 [2777005.001]
  • [Cites] Mod Pathol. 2005 Feb;18 Suppl 2:S81-98 [15502809.001]
  • [Cites] Annu Rev Biochem. 1992;61:1213-30 [1497309.001]
  • [Cites] Curr Opin Cell Biol. 1993 Dec;5(6):1023-8 [8129939.001]
  • [Cites] Jpn J Cancer Res. 1997 Sep;88(9):839-45 [9369931.001]
  • [Cites] Kurume Med J. 1998;45(3):271-8 [9787598.001]
  • [Cites] Crit Rev Toxicol. 1999 Mar;29(2):169-261 [10213111.001]
  • [Cites] J Androl. 1991 May-Jun;12(3):171-9 [1655685.001]
  • (PMID = 19049257.001).
  • [ISSN] 1559-6109
  • [Journal-full-title] Journal of the American Association for Laboratory Animal Science : JAALAS
  • [ISO-abbreviation] J. Am. Assoc. Lab. Anim. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2687134
  •  go-up   go-down


6. McClean GE, Kurian S, Walter N, Kekre A, McCluggage WG: Cervical embryonal rhabdomyosarcoma and ovarian Sertoli-Leydig cell tumour: a more than coincidental association of two rare neoplasms? J Clin Pathol; 2007 Mar;60(3):326-8
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cervical embryonal rhabdomyosarcoma and ovarian Sertoli-Leydig cell tumour: a more than coincidental association of two rare neoplasms?
  • A case in which an embryonal rhabdomyosarcoma of the cervix and an ovarian Sertoli-Leydig cell tumour of intermediate differentiation occurred in a 13-year-old girl is described.
  • The reason for this association, which is thought to be more than coincidental, is not known, although an underlying genetic abnormality is a possibility.
  • The ovarian tumour in this case was characterised by the presence of foci of cells with extremely pleomorphic nuclei, which initially raised the possibility of metastatic rhabdomyosarcoma.
  • These were interpreted as foci of bizarre nuclei within the Sertoli-Leydig cell tumour.
  • [MeSH-major] Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology. Rhabdomyosarcoma, Embryonal / pathology. Sertoli-Leydig Cell Tumor / pathology. Uterine Cervical Neoplasms / pathology

  • Genetic Alliance. consumer health - Rhabdomyosarcoma embryonal.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Chromosomes Cancer. 2002 Mar;33(3):310-21 [11807989.001]
  • [Cites] J Clin Pathol. 2007 Jan;60(1):88-9 [17213352.001]
  • [Cites] Int J Gynecol Pathol. 2004 Jan;23(1):78-82 [14668557.001]
  • [Cites] Mt Sinai J Med. 1971 Jul-Aug;38(4):363-74 [5314782.001]
  • [Cites] Cancer. 1979 Jan;43(1):374-82 [367573.001]
  • [Cites] Medicine (Baltimore). 1983 May;62(3):159-69 [6843355.001]
  • [Cites] Int J Gynecol Pathol. 1983;1(4):325-35 [6309684.001]
  • [Cites] Am J Surg Pathol. 1983 Dec;7(8):755-71 [6660351.001]
  • [Cites] Int J Gynecol Pathol. 1984;3(3):277-90 [6500802.001]
  • [Cites] Am J Surg Pathol. 1985 Aug;9(8):543-69 [3911780.001]
  • [Cites] Cancer. 1987 Oct 1;60(7):1552-60 [3621128.001]
  • [Cites] Gynecol Oncol. 1988 Mar;29(3):290-304 [3278956.001]
  • [Cites] Diagn Mol Pathol. 1993 Jun;2(2):94-8 [8269283.001]
  • [Cites] Mod Pathol. 1995 Jan;8(1):25-30 [7731938.001]
  • [Cites] Gynecol Oncol. 1997 Oct;67(1):102-6 [9345364.001]
  • [Cites] J Reprod Med. 1999 Mar;44(3):306-8 [10202753.001]
  • [Cites] Arch Gynecol Obstet. 2004 Dec;270(4):278-80 [12942264.001]
  • [Cites] Mol Genet Metab. 2003 Feb;78(2):83-92 [12666684.001]
  • (PMID = 17347287.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1860567
  •  go-up   go-down


7. Caringella A, Loizzi V, Resta L, Ferreri R, Loverro G: A case of Sertoli-Leydig cell tumor in a postmenopausal woman. Int J Gynecol Cancer; 2006 Jan-Feb;16(1):435-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of Sertoli-Leydig cell tumor in a postmenopausal woman.
  • Sertoli-Leydig cell tumor belongs to the group of sex cord-stromal tumors of the ovary.
  • These neoplasms account for less than 0.5% of all ovarian tumors and are more often encountered in young women between the ages of 20 and 30 years who usually become virilized.
  • We described an unusual case of Sertoli-Leydig cell tumor in a postmenopausal women who presented with a solid right pelvic mass, a large amount of ascites, and laboratory tests revealing an elevated CA125, all suggesting a pelvic malignancy.
  • Although five similar cases of postmenopausal women with Sertoli-Leydig cell tumor of ovary have been reported in the literature, we believe that this is an useful addition to the literature.
  • [MeSH-major] Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / surgery. Sertoli-Leydig Cell Tumor / diagnosis. Sertoli-Leydig Cell Tumor / surgery
  • [MeSH-minor] Aged. Biopsy, Needle. Female. Follow-Up Studies. Humans. Immunohistochemistry. Neoplasm Staging. Ovariectomy / methods. Postmenopause. Rare Diseases. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16445673.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Kawatra V, Mandal S, Khurana N, Aggarwal SK: Retiform pattern of Sertoli-Leydig cell tumor of the ovary in a 4-year-old girl. J Obstet Gynaecol Res; 2009 Feb;35(1):176-9
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retiform pattern of Sertoli-Leydig cell tumor of the ovary in a 4-year-old girl.
  • Sertoli-Leydig cell tumors are rare sex cord-stromal neoplasms that account for <0.2% of ovarian tumors.
  • These tumors with a retiform pattern pose difficult diagnostic problems, with the majority being misinterpreted as serous papillary cystadenocarcinoma and endodermal sinus tumor.
  • Retiform pattern Sertoli-Leydig cell tumor seen mostly in young patients is clinically malignant and has a worse prognosis, underlining the importance of recognition of this histopathologic entity.
  • Described here is a rare case of ovarian Sertoli-Leydig cell tumor with retiform pattern in a 4-year-old child without any endocrine manifestations.
  • [MeSH-major] Ovarian Neoplasms / pathology. Sertoli-Leydig Cell Tumor / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19215568.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


9. Kataria SP, Mishra K, Dev G, Tandon R: Sertoli-Leydig cell tumor of ovary with heterologous element: a case report. Indian J Pathol Microbiol; 2005 Oct;48(4):493-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sertoli-Leydig cell tumor of ovary with heterologous element: a case report.
  • Sertoli-Leydig cell tumors are uncommon tumors of ovary accounting for about 1% of sex cord stromal tumors.
  • They constitute between 0.1% to 0.5% of all the primary ovarian neoplasms.
  • The majority of reported cases are moderately or poorly differentiated combined Sertoli-Leydig cell tumors.
  • A rare case of Sertoli-Leydig cell tumor with heterologous element in a 14 year girl is described.
  • The heterologous component comprised smooth muscle, an uncommon element, that was seen in 60 to 70% of the tumor area.
  • The epithelial element of the tumor consisted of solid, tubular and foci of retiform pattern.
  • [MeSH-major] Ovarian Neoplasms / pathology. Sertoli-Leydig Cell Tumor / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16366107.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


10. Azuma A, Koyama T, Mikami Y, Tamai K, Fujimoto K, Morisawa N, Nagano F, Yoshioka S, Togashi K: A case of Sertoli-Leydig cell tumour of the ovary with a multilocular cystic appearance on CT and MR imaging. Pediatr Radiol; 2008 Aug;38(8):898-901
MedlinePlus Health Information. consumer health - Ovarian Cysts.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of Sertoli-Leydig cell tumour of the ovary with a multilocular cystic appearance on CT and MR imaging.
  • We present a case of Sertoli-Leydig cell tumour of the ovary in a 14-year-old girl who presented with abdominal distension.
  • Although extensive cyst formation of Sertoli-Leydig cell tumour is rare, this tumour should be considered in the differential diagnosis of a multilocular cystic ovarian tumour in a young female.
  • [MeSH-major] Magnetic Resonance Imaging / methods. Ovarian Cysts / diagnosis. Ovarian Neoplasms / diagnosis. Sertoli-Leydig Cell Tumor / diagnosis. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adolescent. Diagnosis, Differential. Female. Humans

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1985 Aug;9(8):543-69 [3911780.001]
  • [Cites] Cancer. 1982 Dec 1;50(11):2465-75 [7139538.001]
  • [Cites] Radiographics. 1991 Jul;11(4):533-48 [1887110.001]
  • [Cites] Am J Surg Pathol. 1984 Jun;8(6):405-18 [6731664.001]
  • [Cites] Pathol Annu. 1988;23 Pt 1:237-96 [2838794.001]
  • [Cites] Radiographics. 1998 Nov-Dec;18(6):1523-46 [9821198.001]
  • (PMID = 18470510.001).
  • [ISSN] 0301-0449
  • [Journal-full-title] Pediatric radiology
  • [ISO-abbreviation] Pediatr Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


11. Virk R, Lu D: Mucinous adenocarcinoma as heterologous element in intermediately differentiated Sertoli-Leydig cell tumor of the ovary. Pathol Res Pract; 2010 Jul 15;206(7):489-92
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous adenocarcinoma as heterologous element in intermediately differentiated Sertoli-Leydig cell tumor of the ovary.
  • Sertoli-Leydig cell tumor (SLCT) is a rare tumor involving the ovary.
  • SLCT with benign and borderline mucinous neoplasm has been reported in the literature.
  • Herein, we describe a rare case of intermediately differentiated Sertoli-Leydig cell tumor with mucinous adenocarcinoma as the heterologous element in a 21-year-old woman.
  • She presented with throbbing lower abdominal pain and was found to have a large, complex left ovarian mass on imaging studies.
  • Gross examination of the surgical specimen showed a large, encapsulated, solid-cystic mass completely replacing the ovary.
  • Microscopically, the tumor was composed of intermediately differentiated Sertoli-Leydig cell tumor and well-differentiated mucinous adenocarcinoma.
  • Interestingly, the bulk of the tumor (more than 90%) was composed of mucinous adenocarcinoma, whereas the SLCT component comprised less than 10% of the total tumor.
  • The histopathological features and results of immunostaining were consistent with the diagnosis of the intermediately differentiated SLCT with mucinous adenocarcinoma as the heterologous element.
  • This case was a diagnostic challenge as more than 90% of the tumor was composed of mucinous adenocarcinoma and SLCT constituted only the minor part of the tumor.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Ovarian Neoplasms / pathology. Sertoli-Leydig Cell Tumor / pathology
  • [MeSH-minor] Cell Differentiation. Female. Humans. Immunohistochemistry. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009. Published by Elsevier GmbH.
  • (PMID = 19674851.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


12. Dahlgren E, Gull B, Willén R, Sundler F, Rosén T, Jansson PA: Sertoli-Leydig cell tumour in a postmenopausal woman showing all facets of the insulin resistance syndrome (IRS). Ups J Med Sci; 2005;110(3):233-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sertoli-Leydig cell tumour in a postmenopausal woman showing all facets of the insulin resistance syndrome (IRS).
  • Sertoli-Leydig cell tumours are rare sex stromal tumours with an incidence of < 0.5% of all ovarian tumours.
  • Most frequently this tumour occurs in young women with a history of amenorrhoea, hirsutism and lowered pitch.
  • Here, we report on a woman with IRS, postmenopausal virilization and increased testosterone levels due to a Sertoli-Leydig cell tumour.
  • This is the first case to suggest an association between IRS and Sertoli-Leydig cell tumours.
  • Furthermore, we highlight the difficulties in detecting this ovarian tumour with sonography.
  • [MeSH-major] Insulin Resistance. Postmenopause / physiology. Sertoli-Leydig Cell Tumor / complications. Sertoli-Leydig Cell Tumor / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16454160.001).
  • [ISSN] 0300-9734
  • [Journal-full-title] Upsala journal of medical sciences
  • [ISO-abbreviation] Ups. J. Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Sweden
  •  go-up   go-down


13. Gómez-Laguna J, Millán Y, Reymundo C, Domingo V, Martín de Las Mulas J: Bilateral retiform Sertoli-Leydig cell tumour in a bitch. Alpha-inhibin and epithelial membrane antigen as useful tools for differential diagnosis. J Comp Pathol; 2008 Aug-Oct;139(2-3):137-40
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral retiform Sertoli-Leydig cell tumour in a bitch. Alpha-inhibin and epithelial membrane antigen as useful tools for differential diagnosis.
  • Sertoli-Leydig cell tumours with a retiform pattern similar to the pattern of the rete testis are a subtype of sex cord-stromal tumours recognized in the human WHO histological classification of ovarian tumours but not in the equivalent classification for domestic animals.
  • The morphology of the tumour may be confused with that of the more common ovarian epithelial tumours.
  • The gross, microscopical and immunohistochemical features of a canine retiform Sertoli-Leydig cell tumour and its comparison with the human counterpart are presented in this report.
  • Microscopically, the tumour was cystic with tubulopapillary growth characterized by narrow, elongated branching tubules.
  • Immunohistochemically, the tumour cells expressed alpha-inhibin, while epithelial membrane antigen was not detected, indicating a sex cord-stromal origin of the tumour.
  • Additionally, the tumour cells expressed cytokeratin and vimentin in addition to oestrogen receptor alpha and progesterone receptor.
  • [MeSH-major] Dog Diseases / metabolism. Dog Diseases / pathology. Inhibins / biosynthesis. Mucin-1 / biosynthesis. Ovarian Neoplasms / veterinary. Sertoli-Leydig Cell Tumor / veterinary
  • [MeSH-minor] Animals. Diagnosis, Differential. Dogs. Female. Immunohistochemistry. Neoplasms, Glandular and Epithelial / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18620701.001).
  • [ISSN] 0021-9975
  • [Journal-full-title] Journal of comparative pathology
  • [ISO-abbreviation] J. Comp. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Mucin-1; 0 / inhibin-alpha subunit; 57285-09-3 / Inhibins
  •  go-up   go-down


14. Staats PN, Coutts MA, Young RH: Primary ovarian mucinous cystic tumor with prominent theca cell proliferation and focal granulosa cell tumor in its stroma: case report, literature review, and comparison with Sertoli-Leydig cell tumor with heterologous elements. Int J Gynecol Pathol; 2010 May;29(3):228-33
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary ovarian mucinous cystic tumor with prominent theca cell proliferation and focal granulosa cell tumor in its stroma: case report, literature review, and comparison with Sertoli-Leydig cell tumor with heterologous elements.
  • A 73-year-old woman was found to have a 22 cm unilateral multilocular mucinous cystic tumor of the ovary.
  • The stromal component was unusual because of a striking cellular theca cell component in the stroma, which, in turn, merged with a component of adult granulosa cell tumor.
  • The "parent" neoplasm in this case and 3 other similar cases in the literature appears to be the mucinous neoplasm, in contrast with the other example of mucinous neoplasia associated with sex cord neoplasia, the Sertoli-Leydig cell tumor with heterologous elements, in which the "parent" neoplasm is likely the Sertoli-Leydig cell tumor.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Granulosa Cell Tumor / pathology. Ovarian Neoplasms / pathology. Sertoli-Leydig Cell Tumor / pathology. Thecoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20407320.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Poiana C, Virtej I, Carsote M, Banceanu G, Sajin M, Stanescu B, Ioachim D, Hortopan D, Coculescu M: Virilising Sertoli-Leydig cell tumour associated with thyroid papillary carcinoma: case report and general considerations. Gynecol Endocrinol; 2010 Aug;26(8):617-22
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Virilising Sertoli-Leydig cell tumour associated with thyroid papillary carcinoma: case report and general considerations.
  • We present a case of a Sertoli-Leydig cell tumour manifested with progressive hirsutism, frontal alopecia and secondary amenorrhea in a 46-years-old female, evolving for 6 years until presentation.
  • Computed tomography revealed a dense, solid, heterogeneous mass of 3.5/2.8 cm in the right ovary.
  • The histopathological report mentioned a Sertoli-Leydig cell tumor with intermediate grade of differentiation.
  • At 6 months follow-up the diagnosis of a left lobe thyroid nodule leaded to fine needle aspiration biopsy with suspicion of papillary carcinoma.
  • Total thyroidectomy established the diagnosis of thyroid papillary carcinoma (2.17/2.18 cm) T2N0M0, stage II, followed by radioiodine administration.
  • This is to our knowledge the first presented case of ovarian Sertoli-Leydig cell tumour associated with papillary thyroid carcinoma.
  • [MeSH-major] Carcinoma, Papillary / complications. Hirsutism / etiology. Ovarian Neoplasms / complications. Sertoli-Leydig Cell Tumor / complications. Thyroid Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20632913.001).
  • [ISSN] 1473-0766
  • [Journal-full-title] Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
  • [ISO-abbreviation] Gynecol. Endocrinol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


16. Sachdeva P, Arora R, Dubey C, Sukhija A, Daga M, Singh DK: Sertoli-Leydig cell tumor: a rare ovarian neoplasm. Case report and review of literature. Gynecol Endocrinol; 2008 Apr;24(4):230-4
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sertoli-Leydig cell tumor: a rare ovarian neoplasm. Case report and review of literature.
  • BACKGROUND: Sertoli-Leydig cell tumor is a gonadal tumor of the sex cord-stromal type.
  • It is a rare tumor comprising 0.1 to 0.5% of all ovarian tumors.
  • A mass the size of a 28-week gravid uterus was arising from the pelvis.
  • A histopathological diagnosis of Sertoli-Leydig cell tumor (intermediate, Meyers type II) was given.
  • CONCLUSION: Patients with Sertoli-Leydig cell tumors present with signs of defeminization followed by masculinization.
  • Age of the patient, stage of the disease and degree of tumor differentiation based on morphology are the most important factors to consider in the management of the case.
  • [MeSH-major] Ovarian Neoplasms / diagnosis. Sertoli-Leydig Cell Tumor / diagnosis
  • [MeSH-minor] Adolescent. Female. Hirsutism / diagnosis. Hirsutism / etiology. Humans. Ovariectomy. Salpingostomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18382911.001).
  • [ISSN] 0951-3590
  • [Journal-full-title] Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
  • [ISO-abbreviation] Gynecol. Endocrinol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


17. Czernobilsky B, Mamet Y, David MB, Atlas I, Gitstein G, Lifschitz-Mercer B: Uterine retiform sertoli-leydig cell tumor: report of a case providing additional evidence that uterine tumors resembling ovarian sex cord tumors have a histologic and immunohistochemical phenotype of genuine sex cord tumors. Int J Gynecol Pathol; 2005 Oct;24(4):335-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uterine retiform sertoli-leydig cell tumor: report of a case providing additional evidence that uterine tumors resembling ovarian sex cord tumors have a histologic and immunohistochemical phenotype of genuine sex cord tumors.
  • We report a case of a retiform Sertoli-Leydig cell tumor of intermediate differentiation presenting as a uterine intracavity polypoid mass in a 63-year-old woman.
  • In contrast to sertoliform endometrioid carcinoma and to hitherto reported uterine tumors resembling ovarian sex cord tumors (UTROSCTs), which are primarily characterized by tubular glands and solid tubules, this tumor, which most likely represents a UTROSCT, showed a large spectrum of histologic features typical of a genuine retiform Sertoli-Leydig cell tumor.
  • The diagnosis was confirmed by a battery of immunohistochemical stains, which also served as a tool for differential diagnosis with other neoplasms.
  • The tumor cells were positive for broad spectrum keratin (CK) CK18, vimentin, calretinin, and progesterone receptor.
  • The tumor cells were negative for CK7, CK5/6, epithelial membrane antigen (EMA), carcinoembryonic antigen (CEA), carbohydrate antigen 125 (CA125), thrombomodulin, 013 (CD99), melan A, alpha-fetoprotein (AFP), placental alkaline phosphatase (PLAP), alpha-1-antitrypsin, estrogen receptor, S100, neurone specific enolase (NSE), chromogranin, synaptophysin, desmin, caldesmon, and CD10.
  • To the best of our knowledge, no UTROSCT showing such a variety of histologic features indicative of a true sex cord tumor has been reported before.
  • [MeSH-major] Immunohistochemistry. Sertoli-Leydig Cell Tumor / pathology. Sex Cord-Gonadal Stromal Tumors / chemistry. Sex Cord-Gonadal Stromal Tumors / pathology. Uterine Neoplasms / diagnosis. Uterine Neoplasms / pathology
  • [MeSH-minor] Calbindin 2. Cell Differentiation. Diagnosis, Differential. Female. Humans. Keratins / analysis. Middle Aged. Phenotype. Receptors, Progesterone / analysis. S100 Calcium Binding Protein G / analysis. Uterus / pathology. Vimentin / analysis

  • Genetic Alliance. consumer health - Sertoli-leydig cell tumors.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16175078.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CALB2 protein, human; 0 / Calbindin 2; 0 / Receptors, Progesterone; 0 / S100 Calcium Binding Protein G; 0 / Vimentin; 68238-35-7 / Keratins
  •  go-up   go-down


18. Poli UR, Swarnalata G, Maturi R, Rao ST: Recurrent alpha-fetoprotein secreting Sertoli-Leydig cell tumor of ovary with an unusual presentation. Indian J Cancer; 2009 Jan-Mar;46(1):64-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent alpha-fetoprotein secreting Sertoli-Leydig cell tumor of ovary with an unusual presentation.
  • Alpha-fetoprotein secreting (AFP) Sertoli-Leydig cell tumors of ovary (SLCT) are now identified as a distinct entity among the uncommon group of sex cord tumors of ovary.
  • We report an unusual case of recurrent AFP secreting ovarian tumors and as ileocecal mesenteric cyst in a 25-year-old patient resulting in difficulty in initial diagnosis of AFP producing SLCT.
  • [MeSH-major] Cecal Neoplasms / pathology. Ileal Neoplasms / pathology. Leydig Cell Tumor / metabolism. Mesenteric Cyst / pathology. Neoplasm Recurrence, Local / pathology. Ovarian Neoplasms / metabolism. Sertoli Cell Tumor / metabolism. alpha-Fetoproteins / metabolism

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19282570.001).
  • [ISSN] 0019-509X
  • [Journal-full-title] Indian journal of cancer
  • [ISO-abbreviation] Indian J Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  •  go-up   go-down


19. Riggs JC, Zarghami F, Najid K, Haber K, Schreffler SM: Postpartum hemorrhage from ruptured Sertoli-Leydig cell tumor: a case report. J Reprod Med; 2010 Sep-Oct;55(9-10):433-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postpartum hemorrhage from ruptured Sertoli-Leydig cell tumor: a case report.
  • BACKGROUND: Spontaneous postpartum rupture of a Sertoli-Leydig cell ovarian tumor is an infrequent complication of a rare tumor.
  • CASE: A 21-year-old nullipara with an uneventful prenatal course and spontaneous vaginal delivery experienced severe intraabdominal bleeding with hypovolemic shock postpartum from the rupture of a previously undiagnosed Sertoli-Leydig cell ovarian tumor.
  • Diagnosis and intervention were delayed because of the late development of overt signs of intraabdominal bleeding and misleading findings on abdominal examination.
  • CONCLUSION: Rupture of a Sertoli-Leydig cell tumor is a potential cause of postpartum hypovolemic shock resulting from massive intraabdominal bleeding.
  • [MeSH-major] Ovarian Neoplasms / complications. Ovarian Neoplasms / diagnosis. Postpartum Hemorrhage / etiology. Sertoli-Leydig Cell Tumor / complications. Sertoli-Leydig Cell Tumor / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21043371.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Jarzabek K, Philibert P, Koda M, Sulkowski S, Kotula-Balak M, Bilinska B, Kottler ML, Wolczynski S, Sultan C: Primary amenorrhea in a young Polish woman with complete androgen insensitivity syndrome and Sertoli-Leydig cell tumor: identification of a new androgen receptor gene mutation and evidence of aromatase hyperactivity and apoptosis dysregulation within the tumor. Gynecol Endocrinol; 2007 Sep;23(9):499-504
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary amenorrhea in a young Polish woman with complete androgen insensitivity syndrome and Sertoli-Leydig cell tumor: identification of a new androgen receptor gene mutation and evidence of aromatase hyperactivity and apoptosis dysregulation within the tumor.
  • The present paper describes a new de novo non-sense mutation in exon 1 (K141Z) of the androgen receptor gene (AR) and the expression in CAIS testis of aromatase, estrogen receptors, as well as proliferation- and apoptosis-associated proteins.
  • CAIS is a rare disease characterized by absent virilization in 46,XY individuals and the development of a female phenotype despite normal or even elevated androgen levels.
  • Testicular tumors such as Sertoli-Leydig cell tumor often develop in patients with CAIS.
  • The immunohistochemical findings in the testes of our CAIS patient suggest that the high expression of aromatase and other molecular changes in the testis may be responsible for pubertal breast development and the increased risk of testicular tumor.
  • [MeSH-major] Amenorrhea / etiology. Androgen-Insensitivity Syndrome / complications. Androgen-Insensitivity Syndrome / genetics. Apoptosis / genetics. Aromatase / metabolism. Receptors, Androgen / genetics. Sertoli-Leydig Cell Tumor / complications. Testicular Neoplasms / complications


21. Engohan-Aloghe C, Aubain Sommerhausen Nde S, Noël JC: Ovarian involvement by desmoplastic small round cell tumor with leydig cell hyperplasia showing an unusual immunophenotype (cytokeratin negative, calretinin and inhibin positive) mimicking poorly differentiated sertoli leydig cell tumor. Int J Gynecol Pathol; 2009 Nov;28(6):579-83
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian involvement by desmoplastic small round cell tumor with leydig cell hyperplasia showing an unusual immunophenotype (cytokeratin negative, calretinin and inhibin positive) mimicking poorly differentiated sertoli leydig cell tumor.
  • Desmoplastic small round cell tumor (DSRCT) is a rare aggressive tumor primarily involving serosal surfaces in adolescents and young men.
  • Diagnosis is based on specific clinicomorphologic, immunohistochemical, and genetic features.
  • We report here a variant of DSRCT involving the ovaries that mimics the Sertoli-Leydig cell tumor in a 21-year-old woman complaining of abdominal pain.
  • Frozen section examination identified the right ovarian mass as a poorly differentiated Sertoli-Leydig cell tumor.
  • The surgically resected tumor and left ovary and omentum implants found during laparoscopy were diagnosed as DSRCT with Leydig cell hyperplasia.
  • Immunohistochemically, the tumor cells were negative for epithelial markers but were positive for calretinin and inhibin.
  • This case showed that DSRCT with unusual immunohistochemical profiles and Leydig cells hyperplasia pose a diagnostic challenge.
  • [MeSH-major] Carcinoma, Small Cell / pathology. Leydig Cells / pathology. Ovarian Neoplasms / pathology. Sertoli-Leydig Cell Tumor / pathology
  • [MeSH-minor] Adult. Antineoplastic Agents. Calbindin 2. Diagnosis, Differential. Female. Humans. Hyperplasia. Immunohistochemistry. Immunophenotyping. Inhibins / biosynthesis. Male. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / metabolism. Peritoneal Neoplasms / secondary. S100 Calcium Binding Protein G / biosynthesis

  • Genetic Alliance. consumer health - Desmoplastic Small Round Cell Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19851210.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / CALB2 protein, human; 0 / Calbindin 2; 0 / S100 Calcium Binding Protein G; 57285-09-3 / Inhibins
  •  go-up   go-down


22. Ozülker T, Ozpaçaci T, Ozülker F, Ozekici U, Bilgiç R, Mert M: Incidental detection of Sertoli-Leydig cell tumor by FDG PET/CT imaging in a patient with androgen insensitivity syndrome. Ann Nucl Med; 2010 Jan;24(1):35-9
Genetic Alliance. consumer health - Androgen Insensitivity Syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidental detection of Sertoli-Leydig cell tumor by FDG PET/CT imaging in a patient with androgen insensitivity syndrome.
  • The patient had a history of primary amenorrhea and, together with the magnetic resonance imaging findings of absent uterus, short and blind end vagina, a diagnosis of androgen insensitivity syndrome was made.
  • The patient underwent laparoscopic left pelvic mass resection, and the histopathology of the lesion revealed Sertoli-Leydig cell tumor.
  • [MeSH-major] Androgen-Insensitivity Syndrome / complications. Fluorodeoxyglucose F18. Incidental Findings. Sertoli-Leydig Cell Tumor / complications. Sertoli-Leydig Cell Tumor / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19957213.001).
  • [ISSN] 1864-6433
  • [Journal-full-title] Annals of nuclear medicine
  • [ISO-abbreviation] Ann Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


23. Herrera JD, Davidson JA, Mestman JH: Hyperandrogenism due to a testosterone-secreting Sertoli-Leydig cell tumor associated with a dehydroepiandrosterone sulfate-secreting adrenal adenoma in a postmenopausal woman: case presentation and review of literature. Endocr Pract; 2009 Mar;15(2):149-52
Hazardous Substances Data Bank. TESTOSTERONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperandrogenism due to a testosterone-secreting Sertoli-Leydig cell tumor associated with a dehydroepiandrosterone sulfate-secreting adrenal adenoma in a postmenopausal woman: case presentation and review of literature.
  • OBJECTIVE: To report a case of hyperandrogenism attributable to the presence of an adrenal adenoma secreting dehydroepiandrosterone sulfate (DHEA-S) and an ovarian Sertoli-Leydig cell tumor secreting testosterone in a postmenopausal woman.
  • Laboratory tests showed elevated levels of total testosterone (348 ng/dL) and DHEA-S (2,058 microg/dL), and a left adrenal tumor (3 by 4 cm) was detected on abdominal computed tomographic scan.
  • Laparoscopic left adrenalectomy was performed, and the pathologic diagnosis was adrenal adenoma.
  • Transvaginal ultrasonography disclosed an ovarian tumor.
  • Bilateral oophorectomy was performed, and an ovarian Sertoli-Leydig cell tumor was diagnosed.
  • CONCLUSION: After extensive review of the literature, we believe that this is the first reported case of a coincidental DHEA-S-secreting adrenal adenoma and a testosterone- secreting ovarian Leydig cell tumor causing signs of virilization.
  • [MeSH-major] Adrenocortical Adenoma / metabolism. Dehydroepiandrosterone Sulfate / metabolism. Hyperandrogenism / diagnosis. Hyperandrogenism / etiology. Leydig Cell Tumor / metabolism. Testosterone / metabolism

  • Genetic Alliance. consumer health - Hyperandrogenism.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for adrenal adenoma .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19289327.001).
  • [ISSN] 1934-2403
  • [Journal-full-title] Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • [ISO-abbreviation] Endocr Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 3XMK78S47O / Testosterone; 57B09Q7FJR / Dehydroepiandrosterone Sulfate
  • [Number-of-references] 13
  •  go-up   go-down


24. Farinola MA, Gown AM, Judson K, Ronnett BM, Barry TS, Movahedi-Lankarani S, Vang R: Estrogen receptor alpha and progesterone receptor expression in ovarian adult granulosa cell tumors and Sertoli-Leydig cell tumors. Int J Gynecol Pathol; 2007 Oct;26(4):375-82
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Estrogen receptor alpha and progesterone receptor expression in ovarian adult granulosa cell tumors and Sertoli-Leydig cell tumors.
  • The biologic role that estrogen receptor (ER) and progesterone receptor (PR) play in ovarian sex cord-stromal tumors is poorly understood.
  • Furthermore, immunohistochemical data on these hormone receptors in this group of neoplasms are limited and conflicting, with many reports suggesting that expression of ERalpha and/or PR is either infrequent or present at low levels in granulosa and Sertoli cell tumors.
  • Immunohistochemical staining for ERalpha and PR was performed in 69 ovarian sex cord-stromal tumors: 41 adult granulosa cell tumors and 28 Sertoli-Leydig cell tumors.
  • Estrogen receptor alpha and PR were frequently expressed in adult granulosa cell tumors (66% and 98%, respectively) and Sertoli-Leydig cell tumors (79% and 86%, respectively).
  • Diffuse (3+ or 4+) expression of PR was more common in adult granulosa cell tumors (68% vs. 36%; P = 0.013), whereas diffuse (3+ or 4+) expression of ERalpha was more frequent in Sertoli-Leydig cell tumors (50% vs. 20%; P = 0.010).
  • In cases positive for both markers, adult granulosa cell tumors exhibited a focal (1+ or 2+) ERalpha/diffuse (3+ or 4+) PR coordinate profile more commonly than Sertoli-Leydig cell tumors (52% vs. 18%; P = 0.02), whereas Sertoli-Leydig cell tumors displayed a diffuse (3+ or 4+) ERalpha/focal (1+ or 2+) PR profile more frequently than adult granulosa cell tumors (36% vs. 0%; P = 0.0007).
  • We conclude that expression of hormone receptors (based only on frequency of immunostaining) does not allow for distinction from other tumors in the differential diagnosis that are known to be frequently positive for ERalpha and PR such as endometrioid neoplasms.
  • Most adult granulosa cell tumors and Sertoli-Leydig cell tumors share overlapping patterns of expression of ERalpha and PR with each other, but a subset of cases in each tumor category exhibits unique ERalpha/PR immunoprofiles (eg, focal ERalpha/diffuse PR in adult granulosa cell tumors and diffuse ERalpha/focal PR in Sertoli-Leydig cell tumors).
  • These patterns of expression of ERalpha and PR may aid our understanding of the biologic differences between granulosa and Sertoli cell tumors.
  • [MeSH-major] Estrogen Receptor alpha / biosynthesis. Granulosa Cell Tumor / metabolism. Ovarian Neoplasms / metabolism. Receptors, Progesterone / biosynthesis. Sertoli-Leydig Cell Tumor / metabolism
  • [MeSH-minor] Carcinoma, Endometrioid / pathology. Diagnosis, Differential. Female. Humans. Immunohistochemistry

  • Genetic Alliance. consumer health - Sertoli-leydig cell tumors.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17885486.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 0 / Receptors, Progesterone
  •  go-up   go-down


25. McCluggage WG, Young RH: Ovarian sertoli-leydig cell tumors with pseudoendometrioid tubules (pseudoendometrioid sertoli-leydig cell tumors). Am J Surg Pathol; 2007 Apr;31(4):592-7
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian sertoli-leydig cell tumors with pseudoendometrioid tubules (pseudoendometrioid sertoli-leydig cell tumors).
  • The propensity for ovarian endometrioid adenocarcinomas to morphologically mimic Sertoli, Sertoli-Leydig, and granulosa cell tumors, is well known.
  • The converse situation, mimicry of an endometrioid neoplasm by a sex cord-stromal tumor, has not been emphasized.
  • In this report, we describe 9 ovarian Sertoli-Leydig cell tumors (5 well differentiated, 4 of intermediate differentiation) with areas containing hollow, sometimes dilated, tubules which resemble endometrioid glands; we refer to these as pseudoendometrioid tubules.
  • The tumors, all of which were unilateral except for one, ranged from 3.5 to 19 cm and were variously described as tan, pale, yellow, or gold.
  • The proportion of the tumor made up of pseudoendometrioid tubules ranged from 10% to >90%.
  • When widespread, their presence sometimes resulted in consideration of a borderline endometrioid adenofibroma or a well-differentiated endometrioid adenocarcinoma.
  • However, all the neoplasms contained typical Sertoli tubules and one or more of the characteristic patterns of Sertoli-Leydig cell tumors as well as Leydig cells, although the latter cells were inconspicuous in some cases.
  • Immunohistochemistry, performed in 4 cases, showed that the pseudoendometrioid tubules, as well as the more typical Sertoli cell elements, were either positive for alpha inhibin (3 of 4 cases) or calretinin (3 of 4 cases) or both, although sometimes focally so.
  • This report illustrates the potential for ovarian Sertoli-Leydig cell tumors to contain tubules with a pseudoendometrioid appearance which mimic a borderline or malignant endometrioid neoplasm.
  • The presence of more typical Sertoli cell elements and Leydig cells, an absence of squamous elements, endometriosis or associated adenofibroma, and the characteristic immunophenotype assist in diagnosis.
  • [MeSH-major] Ovarian Neoplasms / pathology. Sertoli-Leydig Cell Tumor / pathology
  • [MeSH-minor] Adolescent. Adult. Biomarkers, Tumor / analysis. Carcinoma, Endometrioid / pathology. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Middle Aged

  • Genetic Alliance. consumer health - Sertoli-leydig cell tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17414107.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


26. Rekhi B, Karpate A, Deodhar KK, Chinoy RF: Metastatic rhabdomyosarcomatous elements, mimicking a primary sarcoma, in the omentum, from a poorly differentiated ovarian Sertoli-Leydig cell tumor in a young girl: an unusual presentation with a literature review. Indian J Pathol Microbiol; 2009 Oct-Dec;52(4):554-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic rhabdomyosarcomatous elements, mimicking a primary sarcoma, in the omentum, from a poorly differentiated ovarian Sertoli-Leydig cell tumor in a young girl: an unusual presentation with a literature review.
  • Sertoli-Leydig cell tumors (SLCTs) of the ovary with mesenchymal heterologous elements are uncommon.
  • We report an unusual case in a young girl who presented with an omental mass that was consistent with histopathological features of a high-grade sarcoma, with prominent rhabdomyoblastic differentiation of the embryonal type.
  • The sections from her ovarian mass for which she was operated a year back displayed features of a poorly differentiated SLCT with heterologous elements, including focal rhabdomyoblastic differentiation.
  • This is one of the rare cases, to the best of our knowledge, where only rhabomyosarcomatous elements were identified at the metastatic site, mimicking a primary abdominal rhabdomyosarcoma, in a case of an ovarian SLCT.
  • Further, this case reinforces the presence of rhabdomyosarcomatous elements in an ovarian SLCT to be associated with an aggressive disease course.
  • [MeSH-major] Ovarian Neoplasms / diagnosis. Peritoneal Neoplasms / diagnosis. Peritoneal Neoplasms / secondary. Rhabdomyosarcoma / diagnosis. Rhabdomyosarcoma / secondary. Sertoli-Leydig Cell Tumor / diagnosis
  • [MeSH-minor] Adolescent. Desmin / analysis. Female. Histocytochemistry. Humans. Immunohistochemistry. Keratins / analysis. Omentum / pathology. Ovary / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19805972.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Desmin; 68238-35-7 / Keratins
  • [Number-of-references] 10
  •  go-up   go-down


27. Grove A, Vestergaard V: Ovarian Sertoli-Leydig cell tumor of intermediate grade with heterologous elements of rhabdomyosarcoma. A case report and a review of the literature. Ann Diagn Pathol; 2006 Oct;10(5):288-93
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian Sertoli-Leydig cell tumor of intermediate grade with heterologous elements of rhabdomyosarcoma. A case report and a review of the literature.
  • Ovarian Sertoli-Leydig cell tumors (SLCTs) are rare sex cord-stromal tumors, and among them, tumors with heterologous mesenchymal elements are exceptional and mainly associated with poorly differentiated tumors and are often fatal.
  • We present the fourth case of an ovarian SLCT of intermediate differentiation with rhabdomyosarcoma and a review of the literature.
  • At 4 years control post surgery, the patient was without evidence of disease.
  • Immature skeletal muscle cells in SLCTs often reveal only moderate pleomorphism, and as they are closely admixed with the Sertoli cells or immature gonadal stroma, they can be rather difficult to differentiate from the latter ones.
  • [MeSH-major] Ovarian Neoplasms / pathology. Rhabdomyosarcoma, Embryonal / pathology. Sertoli-Leydig Cell Tumor / pathology
  • [MeSH-minor] Adult. Cell Transformation, Neoplastic / pathology. Female. Gene Expression Regulation, Neoplastic. Humans. Inhibins / genetics. Inhibins / metabolism. Myogenin / genetics. Myogenin / metabolism. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16979522.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Myogenin; 0 / inhibin-alpha subunit; 57285-09-3 / Inhibins
  • [Number-of-references] 19
  •  go-up   go-down


28. Watanabe T, Yamada H, Morimura Y, Abe M, Motoyama T, Sato A: Ovarian Sertoli-Leydig cell tumor with heterologous gastrointestinal epithelium as a source of alpha-fetoprotein: a case report. J Obstet Gynaecol Res; 2008 Jun;34(3):418-21
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian Sertoli-Leydig cell tumor with heterologous gastrointestinal epithelium as a source of alpha-fetoprotein: a case report.
  • Ovarian Sertoli-Leydig cell tumors (SLCT) are rare sex cord stromal neoplasms.
  • To date there have been approximately 25 case reports of ovarian SLCT expressing alpha-fetoprotein (AFP).
  • In such cases, AFP was immunohistochemically detected in the Sertoli cells, Leydig cells, or hepatocytes.
  • A right ovarian tumor was detected and the patient's serum AFP was elevated.
  • On microscopic examination, the tumor was composed of a fibrosarcoma-like area and a poorly differentiated SLCT area with heterologous gastrointestinal epithelium.
  • A recurrent tumor was discovered in the omentum after adjuvant chemotherapy, but serum AFP remained normal.
  • A second laparotomy was performed and the recurrent tumor showed only fibrosarcoma-like features.
  • [MeSH-major] Gastrointestinal Tract / chemistry. Ovarian Neoplasms / diagnosis. Sertoli-Leydig Cell Tumor / diagnosis. alpha-Fetoproteins / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18588618.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  •  go-up   go-down


29. Sun X, Hawkins H, Castro CY, Eltorky MA: Immunohistochemical and ultrastructural analysis of a poorly differentiated pediatric age Sertoli-Leydig cell tumor. Exp Mol Pathol; 2007 Feb;82(1):63-7
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical and ultrastructural analysis of a poorly differentiated pediatric age Sertoli-Leydig cell tumor.
  • Ovarian Sertoli-Leydig cell tumors (SLCT) are rare in young women.
  • Less than 15% of these tumors are poorly differentiated.
  • Clusters of Leydig cells were observed.
  • [MeSH-major] Ovarian Neoplasms / metabolism. Ovarian Neoplasms / ultrastructure. Sertoli-Leydig Cell Tumor / metabolism. Sertoli-Leydig Cell Tumor / ultrastructure
  • [MeSH-minor] Adult. Amenorrhea / etiology. Biomarkers, Tumor / analysis. Calbindin 2. Female. Humans. Immunohistochemistry. Inhibins / metabolism. Microscopy, Electron, Transmission. Obesity / complications. S100 Calcium Binding Protein G / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17022971.001).
  • [ISSN] 0014-4800
  • [Journal-full-title] Experimental and molecular pathology
  • [ISO-abbreviation] Exp. Mol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CALB2 protein, human; 0 / Calbindin 2; 0 / S100 Calcium Binding Protein G; 57285-09-3 / Inhibins
  •  go-up   go-down


30. Youssef A, Ben Ghezala M, Oueslati A, Agrebi W, Oueslati H: [Sertoli-Leydig cell tumor of the ovary]. Tunis Med; 2006 Mar;84(3):209-11
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Sertoli-Leydig cell tumor of the ovary].
  • [Transliterated title] Les tumeurs de Sertoli-Leydig de l'ovaire.
  • Sertoli-Leidig cell tumor of the ovary is a rare tumor.
  • It accounts for 0.5 - 1% of all ovarian tumors.
  • Sertoli-Leidig cell tumors are commonly benign and they occur in young women who desire further childrearing.
  • For the malign Sertoli-Leidig cell tumor, radical treatment is required.
  • The aim of this work is the analysis of clinical, para-clinical and therapeutic aspects of these tumors.
  • [MeSH-major] Ovarian Neoplasms / pathology. Sertoli-Leydig Cell Tumor / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16755966.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


31. Cotte B, Gallot D, Ledoux-Pilon A, Dechelotte P, Rivoire C, Canis M, Mage G: [The use of ultrasonographic 3D power Doppler to describe an ovarian Sertoli-Leydig cell tumor]. Gynecol Obstet Fertil; 2008 May;36(5):532-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The use of ultrasonographic 3D power Doppler to describe an ovarian Sertoli-Leydig cell tumor].
  • [Transliterated title] Description échographique d'une tumeur ovarienne de Sertoli-Leydig à l'aide du doppler énergie tridimensionnel.
  • We report one case of unilateral ovarian Sertoli-Leydig tumor with intermediate grade and heterologous element, in a young woman with clinical and biological typical presentation.
  • [MeSH-major] Ovarian Neoplasms / ultrasonography. Sertoli-Leydig Cell Tumor / ultrasonography. Ultrasonography, Doppler / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18462975.001).
  • [ISSN] 1297-9589
  • [Journal-full-title] Gynécologie, obstétrique & fertilité
  • [ISO-abbreviation] Gynecol Obstet Fertil
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


32. Sala E, Villa N, Crosti F, Miozzo M, Perego P, Cappellini A, Bonazzi C, Barisani D, Dalprà L: Endometrioid-like yolk sac and Sertoli-Leydig cell tumors in a carrier of a Y heterochromatin insertion into 1qh region: a causal association? Cancer Genet Cytogenet; 2007 Mar;173(2):164-9
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrioid-like yolk sac and Sertoli-Leydig cell tumors in a carrier of a Y heterochromatin insertion into 1qh region: a causal association?
  • We describe the case of a young woman showing yolk sac tumors (YST) and a Sertoli-Leydig cell tumor (SLCT) in the right ovary, with recurrences in the right adnexum and with hepatic metastasis.
  • To our knowledge, YST and SLCT have never been described as components of the same tumor or reported as associated in the same patient.
  • LOH analysis revealed 1p36 paternal allele loss in the proband tumor, thus supporting a germ cell origin for the tumor.
  • [MeSH-major] Chromosomes, Human, Pair 1. Chromosomes, Human, Y. Endodermal Sinus Tumor / pathology. Ovarian Neoplasms / pathology. Sertoli-Leydig Cell Tumor / pathology. Translocation, Genetic / genetics

  • Genetic Alliance. consumer health - Sertoli-leydig cell tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17321334.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Heterochromatin
  •  go-up   go-down


33. Greenbaum D, Friedel D: Unanticipated findings at bariatric surgery. Surg Obes Relat Dis; 2005 Jan-Feb;1(1):22-4
MedlinePlus Health Information. consumer health - Peritoneal Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In only three cases (one case each of carcinoid of the appendix, Sertoli-Leydig cell tumor of the ovary, and serous cystadenocarcinoma of the ovary) would there have been a significant difference in the patient's prognosis had the problem been left undiagnosed.
  • [MeSH-major] Incidental Findings. Obesity, Morbid / epidemiology. Ovarian Diseases / epidemiology. Peritoneal Diseases / epidemiology
  • [MeSH-minor] Adult. Aged. Comorbidity. Diverticulitis, Colonic / epidemiology. Female. Humans. Male. Middle Aged. Sigmoid Diseases / epidemiology

  • MedlinePlus Health Information. consumer health - Ovarian Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16925197.001).
  • [ISSN] 1550-7289
  • [Journal-full-title] Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery
  • [ISO-abbreviation] Surg Obes Relat Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Craig ZR, Davis JR, Marion SL, Barton JK, Hoyer PB: 7,12-dimethylbenz[a]anthracene induces sertoli-leydig-cell tumors in the follicle-depleted ovaries of mice treated with 4-vinylcyclohexene diepoxide. Comp Med; 2010 Feb;60(1):10-7
Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 7,12-dimethylbenz[a]anthracene induces sertoli-leydig-cell tumors in the follicle-depleted ovaries of mice treated with 4-vinylcyclohexene diepoxide.
  • Ovarian cancer is associated with high mortality due to its late onset of symptoms and lack of reliable screening methods for early detection.
  • Furthermore, the incidence of ovarian cancer is higher in postmenopausal women.
  • Mice rendered follicle-depleted through treatment with 4-vinylcyclohexene diepoxide (VCD) are a model of ovary-intact menopause.
  • The present study was designed to induce ovarian neoplasia in this model by treating mice with 7,12-dimethylbenz[a]anthracene (DMBA).
  • Female B6C3F1 mice (age, 28 d) received intraperitoneal sesame oil (vehicle; VCD- groups) as a control or VCD (160 mg/kg; VCD+ groups) daily for 20 d to cause ovarian failure.
  • Four months after the onset of dosing, mice from each group received a single injection of DMBA (VCD-DMBA+ and VCD+DMBA+ groups, n = 15 per group) or vehicle control (VCD-DMBA-, n = 15; VCD+ DMBA-, n = 14) under the bursa of the right ovary.
  • Immunohistochemistry was used to confirm classification of neoplasms.
  • None of the animals in the VCD-DMBA- and VCD-DMBA+ groups (that is, mice still undergoing estrus) had tumors at either time point.
  • At the 3-mo time point, 12.5% of the VCD+DMBA+ mice had ovarian tumors; at 5 mo, 57.1% of the VCD+DMBA+ and 14.3% of VCD+DMBA- ovaries had neoplasms.
  • Neoplasms stained positively for inhibin alpha (granulosa cells) and negatively for keratin 7 (surface epithelium), thus confirming classification of the lesions as Sertoli-Leydig cell tumors.
  • These findings provide evidence for an increased incidence of DMBA-induced ovarian neoplasms in the ovaries of follicle-depleted mice compared with that in age-matched cycling controls.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. VINYLCYCLOHEXENE DIOXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Toxicol Lett. 2001 Mar 31;120(1-3):199-208 [11323178.001]
  • [Cites] Crit Rev Oncol Hematol. 2006 Nov;60(2):159-79 [17018256.001]
  • [Cites] Endocrinology. 2001 Aug;142(8):3673-84 [11459817.001]
  • [Cites] Biol Reprod. 2001 Nov;65(5):1489-95 [11673266.001]
  • [Cites] Histopathology. 2002 Apr;40(4):309-26 [11943015.001]
  • [Cites] Endocrinology. 2003 Jan;144(1):69-74 [12488331.001]
  • [Cites] Carcinogenesis. 2003 Feb;24(2):327-34 [12584184.001]
  • [Cites] Biol Reprod. 2004 Jul;71(1):130-8 [14998904.001]
  • [Cites] Reprod Biol Endocrinol. 2003 Oct 7;1:67 [14613552.001]
  • [Cites] Carcinogenesis. 2004 Sep;25(9):1747-55 [15073042.001]
  • [Cites] Gan. 1967 Jun;58(3):253-66 [6081229.001]
  • [Cites] Int J Cancer. 1969 Jan 15;4(1):61-75 [4310334.001]
  • [Cites] J Natl Cancer Inst. 1972 May;48(5):1283-95 [4337905.001]
  • [Cites] Cancer Res. 1973 Apr;33(4):721-3 [4696472.001]
  • [Cites] Cancer Res. 1973 Nov;33(11):2768-73 [4748432.001]
  • [Cites] Gynecol Oncol. 1977 Jun;5(2):161-7 [881128.001]
  • [Cites] Cancer Res. 1984 May;44(5):1827-30 [6713385.001]
  • [Cites] Carcinogenesis. 1984 Aug;5(8):1021-6 [6430583.001]
  • [Cites] Arch Histol Jpn. 1986 Aug;49(3):379-89 [3800599.001]
  • [Cites] Environ Health Perspect. 1987 Aug;73:91-106 [3665872.001]
  • [Cites] Genes Dev. 1990 Mar;4(3):390-400 [1692559.001]
  • [Cites] Cell. 1990 Oct 5;63(1):175-83 [1698554.001]
  • [Cites] Toxicol Appl Pharmacol. 1996 Aug;139(2):394-401 [8806857.001]
  • [Cites] Am J Physiol Renal Physiol. 2007 Jul;293(1):F193-9 [17389681.001]
  • [Cites] Mol Cancer Res. 2008 Jan;6(1):99-109 [18234966.001]
  • [Cites] J Toxicol Environ Health B Crit Rev. 2008 Mar;11(3-4):301-21 [18368558.001]
  • [Cites] J Bone Miner Res. 2008 Aug;23(8):1296-303 [18348702.001]
  • [Cites] Gynecol Oncol. 2009 Mar;112(3):610-5 [19150572.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2009 Sep;297(3):R587-92 [19439618.001]
  • [Cites] J Natl Cancer Inst. 1996 Dec 18;88(24):1810-20 [8961970.001]
  • [Cites] J Biol Chem. 1999 Aug 20;274(34):23963-8 [10446164.001]
  • [Cites] J Exp Zool. 1957 Mar;134(2):207-37 [13428952.001]
  • [Cites] Acta Unio Int Contra Cancrum. 1963;19:779-82 [14050667.001]
  • [Cites] Cancer Res. 2004 Nov 15;64(22):8177-83 [15548682.001]
  • [Cites] Carcinogenesis. 2005 May;26(5):951-7 [15695234.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2005 Sep;25(9):1910-6 [15994440.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2005 Sep;25(9):1765-6 [16127026.001]
  • [Cites] Cell Tissue Res. 2005 Oct;322(1):117-24 [15902502.001]
  • [Cites] Comp Med. 2005 Dec;55(6):523-7 [16422148.001]
  • [Cites] Menopause. 2006 May-Jun;13(3):482-8 [16735946.001]
  • [Cites] J Biomed Opt. 2006 Jul-Aug;11(4):041123 [16965151.001]
  • [Cites] Biol Reprod. 2001 Jul;65(1):87-93 [11420227.001]
  • (PMID = 20158943.001).
  • [ISSN] 1532-0820
  • [Journal-full-title] Comparative medicine
  • [ISO-abbreviation] Comp. Med.
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / ES06694; United States / NIEHS NIH HHS / ES / P30 ES006694; United States / NCI NIH HHS / CA / R01 CA119200; United States / NIA NIH HHS / AG / AG021948; United States / NIA NIH HHS / AG / R01 AG021948; United States / NCI NIH HHS / CA / CA119200
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Cyclohexenes; 0 / Keratin-7; 0 / Krt2-7 protein, mouse; 0 / Vinyl Compounds; 0 / inhibin-alpha subunit; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene; 57285-09-3 / Inhibins; 596C064IG4 / 4-vinyl-1-cyclohexene dioxide
  • [Other-IDs] NLM/ PMC2826079
  •  go-up   go-down


35. Irving JA, Young RH: Granulosa cell tumors of the ovary with a pseudopapillary pattern: a study of 14 cases of an unusual morphologic variant emphasizing their distinction from transitional cell neoplasms and other papillary ovarian tumors. Am J Surg Pathol; 2008 Apr;32(4):581-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granulosa cell tumors of the ovary with a pseudopapillary pattern: a study of 14 cases of an unusual morphologic variant emphasizing their distinction from transitional cell neoplasms and other papillary ovarian tumors.
  • Granulosa cell tumors of the ovary with a pseudopapillary pattern have received only passing mention in the literature.
  • We have reviewed the clinicopathologic features of 10 cases of juvenile granulosa cell tumor and 4 cases of adult granulosa cell tumor with a pseudopapillary pattern.
  • Twelve cases were received in consultation; the referring pathologist favored a diagnosis of a transitional cell neoplasm in 3 of these cases, and a retiform Sertoli-Leydig cell tumor in 2 cases; in most of the remainder, the diagnosis of granulosa cell tumor was considered but uncertainty expressed because of the unusual papillarylike pattern.
  • All 14 tumors were unilateral, and the majority were predominantly cystic, 3 unilocular, and 6 multilocular.
  • In all tumors, thorough sampling revealed areas with architectural patterns and cytomorphology typical of granulosa cell tumor.
  • Granulosa cell tumors of adult and juvenile type may have a pseudopapillary pattern that can be confused with other ovarian tumors with a papillary architecture.
  • Identification of areas that are more characteristic of granulosa cell tumor resolves most cases, although immunohistochemistry can be used in more problematic tumors.
  • This phenomenon seems to be related to the cystic change that is a feature of many granulosa cell tumors.
  • [MeSH-major] Carcinoma, Transitional Cell / pathology. Granulosa Cell Tumor / pathology. Ovarian Neoplasms / pathology. Sertoli-Leydig Cell Tumor / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Diagnosis, Differential. Female. Humans. Immunohistochemistry

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18301054.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Bacha D, Mrad K, Dhouib R, Driss M, Abbes I, Sassi S, Ben Romdhane K: Paraganglioma: report of a rare case with ovarian involvement. Pathologica; 2007 Apr;99(2):50-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paraganglioma: report of a rare case with ovarian involvement.
  • We report a well-documented case of paraganglioma involving right ovary, which was initially misdiagnosed as a Sertoli-Leydig cell tumor and recurred one year later.
  • The right ovarian tumor measured 105x90x60 mm and was associated to a subdiaphragmatic tumor measuring 80x60x35 mm, a peritoneal and a preureteral nodules measuring 10 mm either.
  • Microscopically, tumor cells were arranged in trabeculae and cords separated by a delicate stroma.
  • The tumor expressed neuroendocrine markers (chromogranin, synaptophysin) epithelial membrane antigen and focally cytokeratin 7 and E-cadherin.
  • Pathological ovarian paraganglioma diagnosis could be difficult but one should be aware of its bona fide existence.
  • [MeSH-major] Ovarian Neoplasms / pathology. Paraganglioma / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17633808.001).
  • [ISSN] 0031-2983
  • [Journal-full-title] Pathologica
  • [ISO-abbreviation] Pathologica
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


37. Kim BM, Lee JY, Han YH, Kim SY, Seo JW, Kim YH, Cha SJ, Hur G, Joo M, Lee ES: Mesothelial cyst of the round ligament mimicking a metastasis: a case report. Korean J Radiol; 2010 May-Jun;11(3):364-7
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Clinically, it is frequently misdiagnosed as one of commoner diseases such as an inguinal hernia, femoral hernia, lipoma, and lymphadenopathy upon physical examination.
  • Some previous reports elaborated the sonographic features of a mesothelial cyst of the round ligament.
  • However, to our knowledge, few reports have described the CT features of a mesothelial cyst.
  • We illustrated here the sonographic and multidetector CT features of a case of a mesothelial cyst of the round ligament that presented as an inguinal palpable mass and mimicked a metastasis in a patient with a Sertoli-Leydig cell tumor of the ovary.
  • [MeSH-major] Abdominal Neoplasms / diagnosis. Cysts / radiography. Cysts / ultrasonography. Ovarian Neoplasms / pathology. Round Ligament of Uterus / radiography. Round Ligament of Uterus / ultrasonography. Sertoli-Leydig Cell Tumor / pathology
  • [MeSH-minor] Aged. Contrast Media. Diagnosis, Differential. Epithelium / radiography. Epithelium / ultrasonography. Female. Humans. Radiographic Image Enhancement / methods. Tomography, X-Ray Computed / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Ultrasound Med. 2004 Mar;23(3):429-32 [15055792.001]
  • [Cites] Fertil Steril. 2004 Oct;82(4):944-6 [15482776.001]
  • [Cites] Am J Surg. 1986 Apr;151(4):515-7 [3963310.001]
  • [Cites] AJR Am J Roentgenol. 2005 Jul;185(1):284-5 [15972444.001]
  • [Cites] Br J Radiol. 2004 Mar;77(915):243-4 [15020367.001]
  • [Cites] Pediatr Radiol. 2007 Jun;37(6):603-6 [17453186.001]
  • [Cites] J Ultrasound Med. 2007 Oct;26(10):1449-51 [17901149.001]
  • [Cites] J Ultrasound Med. 2007 Dec;26(12):1735-42 [18029925.001]
  • [Cites] Clin Imaging. 1999 Nov-Dec;23(6):375-6 [10899421.001]
  • [Cites] J Clin Ultrasound. 2007 May;35(4):226-8 [17354251.001]
  • (PMID = 20461192.001).
  • [ISSN] 2005-8330
  • [Journal-full-title] Korean journal of radiology
  • [ISO-abbreviation] Korean J Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Contrast Media
  • [Other-IDs] NLM/ PMC2864865
  • [Keywords] NOTNLM ; Inguinal area / Mesothelial cyst / Multi-detector row CT / Round ligament / Ultrasonography
  •  go-up   go-down


38. Baranova A, Gowder S, Naouar S, King S, Schlauch K, Jarrar M, Ding Y, Cook B, Chandhoke V, Christensen A: Expression profile of ovarian tumors: distinct signature of Sertoli-Leydig cell tumor. Int J Gynecol Cancer; 2006 Nov-Dec;16(6):1963-72
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression profile of ovarian tumors: distinct signature of Sertoli-Leydig cell tumor.
  • Epithelial ovarian tumors are the most common subtype of ovarian cancer.
  • In this study, we reveal distinct expression signatures of previously uncharacterized ovarian carcinoma subtypes, including endometrioid component of mixed ovarian tumor and Sertoli-Leydig tumor.
  • Both subtypes were compared to the most common and well-characterized ovarian epithelial carcinoma of the serous type.
  • Functional analysis of differentially expressed genes in Sertoli-Leydig tumor revealed an upregulation in sonic hedgehog pathway, deregulation of several metabolic pathways especially in amino acid metabolism and overexpression of genes associated with protein synthesis, including ribosomal genes.
  • [MeSH-major] Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Ovarian Neoplasms / genetics. Sertoli-Leydig Cell Tumor / genetics

  • Genetic Alliance. consumer health - Sertoli-leydig cell tumors.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17177833.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1R15CA113331-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger
  •  go-up   go-down


39. Shirley S, Devi VS, Krishnamurthy R, Nabhi MV, Majhi U, Selvaluxmy G: Endometrial adenocarcinoma involving both horns of a bicornuate uterus. J Cancer Res Ther; 2010 Jul-Sep;6(3):304-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial adenocarcinoma involving both horns of a bicornuate uterus.
  • We report a rare case of endometrial adenocarcinoma involving both horns of a bicornuate uterus in a postmenopausal woman.
  • Patient underwent total abdominal hysterectomy with bilateral salpingo-oophorectomy and bilateral pelvic lymph node dissection following an initial positive diagnosis of well differentiated endometrioid adenocarcinoma on endometrial biopsy.
  • Incidentally, the left ovary revealed a well differentiated sertoli leydig cell tumor.
  • Its simultaneous occurrence with an ovarian sertoli leydig cell tumor has not been reported in English literature so far.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21119258.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


40. Stacher E, Pristauz G, Scholz HS, Moinfar F: Bilateral ovarian well-differentiated Sertoli-Leydig cell tumors with heterologous elements associated with unilateral serous cystadenoma--a case report. Int J Gynecol Pathol; 2010 Sep;29(5):419-22
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral ovarian well-differentiated Sertoli-Leydig cell tumors with heterologous elements associated with unilateral serous cystadenoma--a case report.
  • Bilateral Sertoli-Leydig cell tumors (SLCTs) of the ovary, especially in association with a cystadenoma, are exceedingly rare.
  • We present a case of a 61-year-old woman with bilateral well-differentiated SLCTs in which the Sertoli-Leydig cell component showed leiomyogenic (heterologous) differentiation.
  • [MeSH-major] Cystadenoma, Serous / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology. Sertoli-Leydig Cell Tumor / pathology
  • [MeSH-minor] Cell Differentiation. Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Sertoli-leydig cell tumors.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Gynecol Pathol. 2011 Jul;30(4):395 [21623193.001]
  • (PMID = 20736765.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Loeffen JL, Wijnen M, Schijf CP, van Wieringen P: [Ovarian tumour in a girl with chronic abdominal pain and distension]. Ned Tijdschr Geneeskd; 2006 Mar 25;150(12):677-80
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ovarian tumour in a girl with chronic abdominal pain and distension].
  • [Transliterated title] Ovariumtumor bij een meisje met chronische buikpijn en zwelling van de buik.
  • The cause was a Sertoli-Leydig cell tumour originating in the left ovary.
  • The cyst and ovary were resected.
  • Ovarian tumours are rarely seen in children.
  • Two of the most frequently observed sex cord-stromal tumours are the juvenile granulosa cell tumour and the Sertoli-Leydig cell tumour.
  • Even though these tumours may contain histologically malignant characteristics, their behaviour is usually benign.
  • In addition, pressure from the tumour mass may result in symptoms in adjacent organ systems.
  • Patients with advanced disease may benefit from adjuvant chemotherapy.
  • Chronic abdominal pain is frequently observed in children and, in some rare cases, may be caused by ovarian tumours.
  • [MeSH-major] Ovarian Neoplasms / diagnosis. Sertoli Cell Tumor / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16613252.001).
  • [ISSN] 0028-2162
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


42. Onur MR, Firdolas F, Onur R, Kocakoc E, Akpolat N, Orhan I: Scrotal ultrasonography: should it be used in routine evaluation of infertile men? Andrologia; 2008 Feb;40(1):58-61
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Scrotal ultrasonography (US) has an important role in the diagnosis of testicular tumours when not palpable by physical examination.
  • Histopathological examination revealed mixed germ cell tumour and Sertoli-Leydig cell tumour in case 1 and case 2 respectively.
  • [MeSH-major] Infertility, Male / ultrasonography. Neoplasms, Germ Cell and Embryonal / ultrasonography. Scrotum / ultrasonography. Sertoli-Leydig Cell Tumor / ultrasonography. Testicular Neoplasms / ultrasonography

  • MedlinePlus Health Information. consumer health - Male Infertility.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18211304.001).
  • [ISSN] 0303-4569
  • [Journal-full-title] Andrologia
  • [ISO-abbreviation] Andrologia
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


43. Shanbhogue AK, Shanbhogue DK, Prasad SR, Surabhi VR, Fasih N, Menias CO: Clinical syndromes associated with ovarian neoplasms: a comprehensive review. Radiographics; 2010 Jul-Aug;30(4):903-19
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical syndromes associated with ovarian neoplasms: a comprehensive review.
  • Functional ovarian neoplasms have unique clinical manifestations related to hormone overproduction and may give rise to a broad spectrum of clinical syndromes.
  • Sex cord-stromal tumors, the most common functional ovarian neoplasms, are associated with either hyperestrogenism (as in granulosa cell tumor and thecoma) or hyperandrogenism (as in Sertoli-Leydig cell tumor and Leydig cell tumor).
  • Other, less common ovarian neoplasms that may have endocrine or nonendocrine syndromic manifestations include germ cell tumors associated with the excessive production of human chorionic gonadotropin (eg, choriocarcinoma, dysgerminoma), monodermal teratomas (eg, carcinoid tumor, struma ovarii) associated with carcinoid syndrome and hyperthyroidism, and primary epithelial ovarian cancers associated with paraneoplastic syndromes.
  • The application of diagnostic algorithms based on patient demographic information, clinical manifestations, laboratory findings, and cross-sectional imaging features may help identify ovarian neoplasms in complex clinical settings.
  • [MeSH-major] Diagnostic Imaging / methods. Endocrine System Diseases / diagnosis. Ovarian Neoplasms / diagnosis. Paraneoplastic Syndromes / diagnosis

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • MedlinePlus Health Information. consumer health - Endocrine Diseases.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20631359.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


44. Young RH: A brief history of the pathology of the gonads. Mod Pathol; 2005 Feb;18 Suppl 2:S3-S17
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Knowledge of testicular tumor pathology dates back to the great British workers Percival Pott and Sir Astley Cooper but the single greatest early stride was made with the description in 1906 by the French urologist Maurice Chevassu of the seminoma.
  • The seminal 1946 paper of Nathan B Friedman and Robert A Moore, which segregated out as a distinct entity embryonal carcinoma, is, however, the foundation for the current classification of testicular tumors.
  • In that year Pierre Masson described the distinctive neoplasm, the spermatocytic seminoma.
  • The 1950s saw the publication of an important paper by Frank J Dixon and Dr Moore and they also wrote the first series fascicle on testicular tumors.
  • In this same timeframe, and thereafter, Robert E Scully made significant contributions to testicular pathology, writing the first English language paper on spermatocytic seminoma, describing several subtypes of sex cord tumor, and also the distinctive lesion of intersex, the gonadoblastoma, as well as playing a major role in 1980 in formulating the current classification of premalignant lesions of the testis.
  • The current classification of testicular tumors was arrived at in the early 1970s when the World Health Organization, under the leadership of Dr FK Mostofi, who himself made notable contributions to testicular pathology, devised what is fundamentally the current classification of neoplasms of the male gonad.
  • Although comments on ovarian pathology were made by such legendary figures of earlier times as Giovanni Battista Morgagni and Matthew Baillie, it is only in the mid to later years of the 19th century that contributions, mostly in Europe, began to move knowledge of ovarian pathology to its current state.
  • Thomas Hodgkin, Richard Bright, and Sir James Paget all wrote extensively on ovarian neoplasms.
  • In 1870, Heinrich Waldeyer, and later in that century, another German, Hermann Johannes Pfannenstiel wrote important papers on the surface epithelial tumors.
  • Their work was followed by that of Robert Meyer who made monumental contributions to gynecological pathology, including recognizing the Brenner tumor as a distinctive neoplasm and proposing the first classification of Sertoli-Leydig cell tumors (arrhenoblastomas).
  • He also coined the term 'disgerminoma' (soon changed to dysgerminoma) for the ovarian tumor that had been described in detail by the French investigator Marcel Chenot 5 years after Chevassu had mentioned the tumor in his paper describing the seminoma.
  • During the Meyer era other significant contributions were made by, among others, Howard C Taylor writing on the borderline tumors and John A Sampson writing on endometriosis and tumors, associated with it.
  • Dr Teilum delineated the morphologic features of the yolk sac tumor and noted the resemblance of papillary formations within it to the endodermal sinuses of the rat placenta.
  • He also wrote extensively on sex cord tumors in both gonads.
  • At a FIGO meeting in 1961 Dr Santesson played a major role in formulating the first organized classification of the surface epithelial-stromal tumors of the ovary and also promoted the endometrioid carcinoma as a special variant of ovarian cancer.
  • In a career spanning over 50 years, Dr Scully was the architect of the modern classification of ovarian tumors being the driving force behind the influential 1973 World Health Organization classification of them.
  • His many original observations have touched upon virtually all categories of ovarian tumor pathology.
  • His second series fascicle 'Tumors of the Ovaries and Maldeveloped Gonads' utilized the WHO classification and presented a lucid elaboration of his by then vast experience with ovarian tumors.
  • [MeSH-major] Gonads / pathology. Ovarian Neoplasms / history. Pathology / history. Testicular Neoplasms / history

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15529187.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Biography; Historical Article; Journal Article; Portraits
  • [Publication-country] United States
  • [Personal-name-as-subject] Chevassau M; Moore RA; Mostofi FK; Teilum G; Meyer R; Santesson L; Scully RE
  •  go-up   go-down


45. Fujibayashi M, Aiba M, Iizuka E, Igarashi A, Muraoka M, Takagi K: Granulosa cell tumor-like variant of endometrioid carcinoma of the ovary exhibiting nuclear clearing with biotin activity: a subtype showing close macroscopic, cytologic, and histologic similarity to adult granulosa cell tumor. Arch Pathol Lab Med; 2005 Oct;129(10):1288-94
Hazardous Substances Data Bank. BIOTIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granulosa cell tumor-like variant of endometrioid carcinoma of the ovary exhibiting nuclear clearing with biotin activity: a subtype showing close macroscopic, cytologic, and histologic similarity to adult granulosa cell tumor.
  • CONTEXT: The sex cord-like variant of endometrioid carcinoma of the ovary shows many similarities to Sertoli-Leydig cell tumor and granulosa cell tumor.
  • However, few cases of the granulosa cell tumor-like variant have been reported, suggesting this tumor might often be hidden under the diagnosis of granulosa cell tumor.
  • OBJECTIVE: To investigate the similarities and differences between the granulosa cell tumor-like variant of endometrioid carcinoma and granulosa cell tumor of the ovary and to evaluate a newly observed feature, namely, nuclear clearing (or optically clear nuclei), in this variant tumor.
  • DESIGN: A comparative macroscopic, cytologic, histopathologic, and immunohistochemical study in specimens obtained from the following patients: 1 patient with granulosa cell tumor-like variant of endometrioid carcinoma diagnosed by frozen section examination, 3 patients with granulosa cell tumor, and 6 patients with classic endometrioid carcinoma.
  • RESULTS: The granulosa cell tumor-like variant showed close macroscopic, cytologic, and microscopic similarities to granulosa cell tumor.
  • However, the 2 tumors could be differentiated immunohistochemically.
  • CONCLUSION: Because the granulosa cell tumor-like variant is pathologically similar to granulosa cell tumor, showing only some dissimilarities to the latter, it can easily be misdiagnosed if the possibility of this variant is not kept in mind.
  • Identification of the typical endometrioid histologic features or related lesions or immunohistochemistry may lead to a proper diagnosis.
  • The observation of nuclear clearing with biotin activity in nonmorular nests suggests that this tumor has endometrioid epithelial characteristics.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Cell Nucleus / pathology. Granulosa Cell Tumor / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Biotin / analysis. Carcinoma in Situ / chemistry. Carcinoma in Situ / pathology. Cytodiagnosis. Female. Humans. Immunoenzyme Techniques. Middle Aged

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Arch Pathol Lab Med. 2008 Aug;132(8):1222. Okamura, Mitsue [corrected to Muraoka, Mitsue]
  • (PMID = 16196518.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 6SO6U10H04 / Biotin
  •  go-up   go-down


46. Farah-Klibi F, Ben Slama S, Ben Hamouda S, Sfar R, Koubâa A, Ben Jilani S, Zermani R: [Diagnostic value of immunohistochemistry in ovarian sex cord-stromal tumors]. Tunis Med; 2008 Sep;86(9):821-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnostic value of immunohistochemistry in ovarian sex cord-stromal tumors].
  • [Transliterated title] Apport de l'immunohistochimie dans le diagnostic des tumeurs stromales de l'ovaire.
  • BACKGROUND: The ovarian tumors' diagnosis is based on biological and radiologic tests but only the histological examination associated to an immunohistochemical study allow best diagnosis.
  • AIM: The purposes of this study is to examine inhibin and other markers immunoreactivity to ovarian sex cord-stromal tumors and their histological mimics and to discuss its value in the differential diagnosis.
  • METHODS: We report a retrospective study of 31 cases of ovarian sex cord-stromal tumors and review the clinical, pathologic and immunohistochimical features of these tumors.
  • Immunostaining for inhibin was positive in 66% of granulosa cell tumor, in 50% of Sertoli-Leydig cell tumor and in 54% of thecoma-fibroma group.
  • CONCLUSION: The results of this study show that although it is not complete specificity, inhibin, contrarily to the other markers, can be used to help in the distinction between ovarian sex cord-stromal neoplasms and the other primary and metastatic tumors.
  • [MeSH-major] Ovarian Neoplasms / pathology. Sex Cord-Gonadal Stromal Tumors / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19472783.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


47. Niedziela M: Virilizing ovarian tumor in a 14-year-old female with a prior familial multinodular goiter. Pediatr Blood Cancer; 2008 Oct;51(4):543-5
SciCrunch. Clinical Genomic Database: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Virilizing ovarian tumor in a 14-year-old female with a prior familial multinodular goiter.
  • The dexamethasone suppression test confirmed the hormonal autonomy and magnetic resonance imaging (MRI) visualized a solid tumor within the left ovary.
  • The pathological diagnosis after left salpingo-oophorectomy was Sertoli-Leydig cell tumor.
  • The patient has remained disease-free for 6 years.
  • [MeSH-major] Goiter / pathology. Ovarian Neoplasms / pathology. Virilism / pathology

  • Genetic Alliance. consumer health - Virilizing ovarian tumor.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • SciCrunch. OMIM: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18570301.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Cathro HP, Stoler MH: The utility of calretinin, inhibin, and WT1 immunohistochemical staining in the differential diagnosis of ovarian tumors. Hum Pathol; 2005 Feb;36(2):195-201
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The utility of calretinin, inhibin, and WT1 immunohistochemical staining in the differential diagnosis of ovarian tumors.
  • Calretinin has been proposed as a novel marker of ovarian sex cord-stromal tumors (SCST); this study aims to determine whether calretinin can complement or supplant the established utility of inhibin in the differential diagnosis of SCST.
  • WT1 has been shown to be expressed in ovarian serous, but not mucinous neoplasms; its expression in a variety of ovarian tumors is also examined.
  • Formalin-fixed, paraffin-embedded archival tissues from 111 primary ovarian tumors were analyzed with commercially available antibodies using semi-automated immunohistochemistry.
  • Of 27 SCST, 56% were calretinin and 56% inhibin positive overall; 90% of granulosa cell tumors, 57% of Sertoli-Leydig cell tumors, 33% of thecomas, and 14% of fibromas were calretinin positive.
  • Inhibin was expressed in 60% of granulosa cell tumors, 71% of Sertoli-Leydig cell tumors, 43% of fibromas, and 33% of thecomas.
  • Of 35 surface epithelial tumors (SET), 8% of serous papillary tumors were calretinin positive, whereas 8% of serous papillary tumors and 13% of poorly differentiated carcinomas expressed inhibin.
  • WT1 was expressed in 29% of all endometrioid carcinomas, 10% of borderline mucinous tumors, and no mucinous carcinomas; however, most of the other SETs were positive (77% serous papillary and 88% poorly differentiated carcinomas).
  • Among the SCST, WT1 stained only granulosa cell tumors (75%), though often weakly or variably.
  • Calretinin has only slightly greater sensitivity (76% versus 65%) and equal specificity to inhibin (92%) in the differential staining of granulosa or Sertoli-Leydig cell tumors, that is, nonstromal SCST.
  • Although WT1 should be reliably positive in non-mucinous SET, staining of granulosa cell tumors and lack of expression in a sizable subset of endometrioid carcinomas may confound interpretation.
  • [MeSH-major] Adenocarcinoma / metabolism. Inhibins / metabolism. Ovarian Neoplasms / metabolism. S100 Calcium Binding Protein G / metabolism. Sex Cord-Gonadal Stromal Tumors / metabolism. WT1 Proteins / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Calbindin 2. Cell Count. Diagnosis, Differential. Female. Humans. Immunoenzyme Techniques / methods. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15754297.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CALB2 protein, human; 0 / Calbindin 2; 0 / S100 Calcium Binding Protein G; 0 / WT1 Proteins; 57285-09-3 / Inhibins
  •  go-up   go-down


49. Irving JA, McCluggage WG: Ovarian spindle cell lesions: a review with emphasis on recent developments and differential diagnosis. Adv Anat Pathol; 2007 Sep;14(5):305-19
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian spindle cell lesions: a review with emphasis on recent developments and differential diagnosis.
  • Ovarian lesions composed of spindle cells comprise a heterogeneous group; most are neoplastic but several non-neoplastic conditions are also composed of spindle cells.
  • This review discusses the main differential diagnoses of an ovarian spindle cell lesion, especially concentrating on the recent literature.
  • The majority of ovarian spindle cell lesions fall into the broad category of fibromatous neoplasms whereas others in the sex cord-stromal group may also be composed of spindle cells, including thecomas, granulosa, and Sertoli-Leydig cell tumors and rarer neoplasms, such as sclerosing stromal tumor and signet-ring stromal tumor.
  • In the recent past there have been several major contributions on various aspects of ovarian spindle cell lesions, including cellular and mitotically active cellular fibromatous lesions, smooth muscle neoplasms, and metastatic gastrointestinal stromal tumors.
  • Other mesenchymal or epithelial tumors and mixed epithelial and mesenchymal neoplasms may also enter into the differential diagnosis of an ovarian spindle cell lesion.
  • Several non-neoplastic lesions may be composed of spindle cells, including massive edema, ovarian fibromatosis, stromal hyperplasia, and stromal hyperthecosis.
  • Morphology remains the mainstay in diagnosis but immunohistochemistry may be invaluable in certain circumstances, one example being the identification of a metastatic gastrointestinal stromal tumor within the ovary.
  • [MeSH-major] Carcinoma / diagnosis. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Pathology, Surgical / methods. Pathology, Surgical / trends

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17717430.001).
  • [ISSN] 1072-4109
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 101
  •  go-up   go-down


50. McKenna M, Kenny B, Dorman G, McCluggage WG: Combined adult granulosa cell tumor and mucinous cystadenoma of the ovary: granulosa cell tumor with heterologous mucinous elements. Int J Gynecol Pathol; 2005 Jul;24(3):224-7
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined adult granulosa cell tumor and mucinous cystadenoma of the ovary: granulosa cell tumor with heterologous mucinous elements.
  • We describe an unusual ovarian neoplasm in a 57-year-old woman composed of an admixture of mucinous cystadenoma and adult granulosa cell tumor (AGCT).
  • Theories of histogenesis include a collision tumor and heterologous mucinous differentiation within an AGCT.
  • Because heterologous mucinous elements are well described in other ovarian sex-cord-stromal neoplasms, especially but not exclusively Sertoli Leydig cell tumors, it is not unexpected that a similar phenomenon could occur in an AGCT.
  • We review the previously reported cases of combined mucinous cystadenoma and granulosa cell tumor of the ovary.
  • [MeSH-major] Cystadenoma, Mucinous / pathology. Granulosa Cell Tumor / pathology. Ovarian Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Gynecol Pathol. 2012 Jul;31(4):335-6 [22653346.001]
  • (PMID = 15968196.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 18
  •  go-up   go-down


51. Zhang M, Cheung MK, Shin JY, Kapp DS, Husain A, Teng NN, Berek JS, Osann K, Chan JK: Prognostic factors responsible for survival in sex cord stromal tumors of the ovary--an analysis of 376 women. Gynecol Oncol; 2007 Feb;104(2):396-400
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors responsible for survival in sex cord stromal tumors of the ovary--an analysis of 376 women.
  • OBJECTIVE: To evaluate prognostic factors that impact on the survival of women with ovarian sex cord stromal tumors (SCST).
  • METHODS: Data including age at diagnosis, stage, histology, grade, treatment, and survival were extracted from the 1988-2001 Surveillance, Epidemiology, and End Results Program.
  • RESULTS: 376 women (median age: 51) with ovarian sex cord stromal cell tumors were identified, including 339 with granulosa cell and 37 with Sertoli-Leydig cell tumors.
  • 265 (71%) patients had stage I, 39 (10%) stage II, 40 (11%) stage III, and 32 (8%) had stage IV disease.
  • Women with stage I-II disease had a 5-year disease-specific survival of 95% compared to 59% in those with stage III-IV cancers (p<0.001).
  • 110 patients with stage I-II disease underwent conservative surgery without hysterectomy.
  • On multivariate analysis, age<or=50 (p=0.001) and early-stage disease (p<0.001) remained significant prognostic factor for improved survival.
  • CONCLUSIONS: Younger age and early-stage disease are important predictors for improved survival in patients with ovarian sex cord stromal tumors.
  • [MeSH-major] Ovarian Neoplasms / mortality. Ovarian Neoplasms / surgery. Sex Cord-Gonadal Stromal Tumors / mortality. Sex Cord-Gonadal Stromal Tumors / surgery
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Child. Female. Humans. Middle Aged. Neoplasm Staging. Prognosis. Proportional Hazards Models. Risk Factors. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17030354.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Zhao C, Vinh TN, McManus K, Dabbs D, Barner R, Vang R: Identification of the most sensitive and robust immunohistochemical markers in different categories of ovarian sex cord-stromal tumors. Am J Surg Pathol; 2009 Mar;33(3):354-66
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of the most sensitive and robust immunohistochemical markers in different categories of ovarian sex cord-stromal tumors.
  • Different immunohistochemical sex cord-stromal markers have been previously studied in various types of ovarian sex cord-stromal tumors; however, the sensitivity for sex cord-stromal lineage may vary between markers, and some markers may not be as sensitive in some types of sex cord-stromal tumors compared with other tumors in this spectrum of neoplasms.
  • The goals of this study were to determine which immunohistochemical markers are the most sensitive and immunohistochemically robust for sex cord-stromal lineage within a given type of ovarian sex cord-stromal tumor, and to establish whether there are substantial differences of expression of these markers between different types of sex cord-stromal tumors.
  • Immunohistochemical stains for markers which have known variable specificity for sex cord-stromal lineage [inhibin, calretinin, MART-1/melan-A, CD99, steroidogenic factor 1 (SF-1, adrenal 4-binding protein), and WT1], were performed in 127 cases of 5 different types of ovarian sex cord-stromal tumors: adult granulosa cell tumor (n=32), Sertoli cell tumor (n=27), Sertoli-Leydig cell tumor (n=18), steroid cell tumor (n=25), and fibroma/fibrothecoma (n=25).
  • All cases in each type of sex cord-stromal tumor expressed SF-1.
  • Inhibin and calretinin were expressed in all groups of tumors but with a lesser frequency (56% to 100% and 36% to 100% of cases, respectively).
  • All types of tumors except steroid cell tumor expressed WT1.
  • Fibroma/fibrothecoma was the only type of tumor that did not express CD99.
  • The only tumor groups that showed expression of MART-1 were Sertoli-Leydig cell tumor (restricted to the Leydig cell component) and steroid cell tumor (94% and 96% of cases, respectively).
  • The type of sex cord-stromal tumor that was least frequently positive for several of the different markers studied was fibroma/fibrothecoma.
  • Among all tumor groups combined, inhibin and WT1 were the 2 markers showing the most diffuse expression.
  • Likewise, the single marker showing the most optimal combination of diffuse and strong staining (immunohistochemical composite score: possible range, 1 to 12) varied between tumors: adult granulosa cell tumor-inhibin (score 10.0); Sertoli cell tumor-WT1 (score 10.8); Sertoli-Leydig cell tumor (Sertoli cell component)-WT1 (score 10.4); steroid cell tumor-inhibin (score 11.2); and fibroma/fibrothecoma-WT1 (score 8.9).
  • Although each of the different types of sex cord-stromal tumors has a slightly unique immunoprofile in terms of frequency and extent of expression, these differences are relatively minor for most types of tumors with certain exceptions (eg, WT1 is not diagnostically useful in steroid cell tumor; CD99 is not diagnostically useful in fibroma/fibrothecoma; the only sex cord-stromal tumor for which MART-1 is diagnostically useful is steroid cell tumor; inhibin and calretinin are less diagnostically useful in fibroma/fibrothecoma than in the other types of tumors, but expression in fibrothecoma was higher than in fibroma).
  • SF-1 is the most sensitive sex cord-stromal marker among the most common types of sex cord-stromal tumors.
  • Given the findings relating to sensitivity and extent of expression in this study, and known specificity in the literature, the most informative sex cord-stromal markers to be used for the distinction from nonsex cord-stromal tumors are inhibin, calretinin, SF-1, and WT1 (the exact number of markers to be used should be based on the degree of difficulty of the case and level of experience of the pathologist); however, the utility of immunohistochemistry for the diagnosis of fibroma/fibrothecoma is somewhat limited.
  • [MeSH-major] Biomarkers, Tumor / analysis. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology. Sex Cord-Gonadal Stromal Tumors / metabolism. Sex Cord-Gonadal Stromal Tumors / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19033865.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


53. Young RH: Sex cord-stromal tumors of the ovary and testis: their similarities and differences with consideration of selected problems. Mod Pathol; 2005 Feb;18 Suppl 2:S81-98
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sex cord-stromal tumors of the ovary and testis: their similarities and differences with consideration of selected problems.
  • Gonadal sex cord-stromal tumors contain some of the most morphologically interesting neoplasms of the gonads and these lead to many important issues in differential diagnosis.
  • The pathology of these tumors is reviewed with emphasis on new information, similarities and differences in the two gonads, and diagnostic problems.
  • Sertoli cell tumors occur in both gonads being more common in the testis where they usually exhibit a lobular pattern of hollow or solid tubules.
  • In the ovary, tubular differentiation is usually the predominant feature but the lobulation typically seen in the testis is generally not as striking.
  • One variant of Sertoli cell tumor, the large cell calcifying form, appears to be restricted to the male gonad and in contrast to other sex cord tumors is much more frequently bilateral and is associated in many cases with unusual clinical manifestations.
  • In females, it is in the form of the sex cord with annular tubules whereas in males, the lesion has features that are often intermediate between those of a sex cord tumor with annular tubules and a large cell calcifying Sertoli cell tumor.
  • Sertoli-Leydig cell tumors are more morphologically diverse than pure Sertoli cell tumors and for practical purposes are an issue only in ovarian pathology being exceptionally rare in the testis.
  • The classification proposed by Meyer into well, intermediate, and poor differentiation, remains important prognostically.
  • Heterologous tumors most often contain mucinous epithelium, sometimes with small foci of carcinoid or less commonly, and generally in poorly differentiated neoplasms, rhabdomyosarcoma or fetal-type cartilage.
  • Such tumors should be distinguished from pure sarcomas and teratomas.
  • The retiform neoplasms, which tend to occur in young females, may mimic serous borderline tumors or even serous carcinomas.
  • Granulosa cell tumors are much more common in females and in both gonads are divided into adult and juvenile forms.
  • In females, granulosa cell tumors and other sex cord tumors may have markedly bizarre nuclei potentially leading to overdiagnosis as more malignant neoplasms.
  • The juvenile granulosa cell tumor of the testis tends to occur in the first 6 months of life and should be carefully distinguished from the yolk sac tumor of the testis, which usually occurs in a slightly older age group.
  • Occasional sex cord-stromal tumors cannot be readily categorized into the Sertoli or granulosa families and are diagnosed as sex cord-stromal tumors unclassified.
  • In females, this is a relatively common placement for a neoplasm in a pregnant patient.
  • Unclassified tumors are overall more common in males and may entrap residual normal germ cells potentially leading to the erroneous placement of the tumor in the category of a mixed germ cell sex cord-stromal tumor.
  • From the practical viewpoint, the most helpful immunohistochemical findings are the negative staining of sex cord tumors for epithelial membrane antigen, and positive staining for inhibin and calretinin, findings that are converse to those seen in endometrioid carcinomas of the ovary, which commonly have formations that simulate sex cord tumors.
  • [MeSH-major] Ovarian Neoplasms / pathology. Sex Cord-Gonadal Stromal Tumors / pathology. Testicular Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Female. Granulosa Cell Tumor / pathology. Humans. Male. Sertoli Cell Tumor / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15502809.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 69
  •  go-up   go-down


54. Jung SE, Rha SE, Lee JM, Park SY, Oh SN, Cho KS, Lee EJ, Byun JY, Hahn ST: CT and MRI findings of sex cord-stromal tumor of the ovary. AJR Am J Roentgenol; 2005 Jul;185(1):207-15
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CT and MRI findings of sex cord-stromal tumor of the ovary.
  • OBJECTIVE: The purpose of this article was to research the clinical and imaging features of sex cord-stromal tumors of the ovary to help in specific diagnosis of ovarian tumors.
  • Sex cord-stromal tumors of the ovary are rare ovarian neoplasms, which arise from stromal cells and primitive sex cords in the ovary.
  • The common types are granulosa cell tumors, fibrothecomas, sclerosing stromal tumors, and Sertoli-Leydig cell tumors.
  • They account for most of the hormonally active ovarian tumors.
  • They have characteristic imaging features in each type of the tumor.
  • CONCLUSION: Clinical and radiologic clues are helpful in differential diagnosis from the more common epithelial tumors; sex cord-stromal tumors primarily are treated surgically and have generally good prognosis.
  • [MeSH-major] Magnetic Resonance Imaging. Ovarian Neoplasms / diagnosis. Sex Cord-Gonadal Stromal Tumors / diagnosis. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15972425.001).
  • [ISSN] 0361-803X
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Howell L, Bader A, Mullassery D, Losty P, Auth M, Kokai G: Sertoli Leydig cell ovarian tumour and gastric polyps as presenting features of Peutz-Jeghers syndrome. Pediatr Blood Cancer; 2010 Jul 15;55(1):206-7
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sertoli Leydig cell ovarian tumour and gastric polyps as presenting features of Peutz-Jeghers syndrome.
  • We report a case of Peutz-Jeghers syndrome (PJS) in a 2-year old with precocious puberty secondary to a Sertoli-Leydig cell tumour.
  • The tumour was excised and the STK11 gene deletion identified in both patient and father.
  • [MeSH-major] Gastric Mucosa / pathology. Hamartoma / diagnosis. Ovarian Neoplasms / diagnosis. Peutz-Jeghers Syndrome / diagnosis. Polyps / diagnosis. Sertoli-Leydig Cell Tumor / diagnosis. Stomach Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Peutz Jeghers syndrome.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20310004.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.1.- / STK11 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


56. Llarena Ibarguren R, Azurmendi Sastre V, Padilla Nieva J, Pertusa Peña C: [Non germinal cell testicular tumors]. Arch Esp Urol; 2005 Dec;58(10):1031-4
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Non germinal cell testicular tumors].
  • [Transliterated title] Tumores no germinales de testículo.
  • OBJECTIVES: We report a review of all patients with testicular tumors undergoing surgery in our Hospital over a 13 year period.
  • There were 151 cases, 50 of them were reported as non germ cell tumors (33%).
  • METHODS/RESULTS: 42% of them were haematopoietic tumors, lymphomas and leukemias.
  • 30% of them were non neoplastic tumors, including vascular tumors and granulomatous orchitis.
  • 12% were identified as Leydig or Sertoli cell tumors.
  • CONCLUSIONS: Non germ cell tumors were more frequent in adults (78%) than in children (22%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16482852.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


57. McCluggage WG, McKenna M, McBride HA: CD56 is a sensitive and diagnostically useful immunohistochemical marker of ovarian sex cord-stromal tumors. Int J Gynecol Pathol; 2007 Jul;26(3):322-7
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD56 is a sensitive and diagnostically useful immunohistochemical marker of ovarian sex cord-stromal tumors.
  • Ovarian sex cord-stromal tumors comprise a heterogeneous group of neoplasms with wide morphological diversity, and they can be mistaken for a variety of other tumors.
  • Some types, including granulosa and Sertoli cell tumor, may be confused with a neuroendocrine neoplasm.
  • CD56 is a widely used neuroendocrine marker with a high sensitivity for neuroendocrine tumors and is commonly used as part of a panel to distinguish between a neuroendocrine neoplasm and other tumors in the differential diagnosis.
  • In this study, we investigate CD56 staining in ovarian sex cord-stromal tumors.
  • We stained a large series of ovarian sex cord-stromal neoplasms (n = 85) with CD56.
  • Neoplasms studied were adult granulosa cell tumor (n = 40), juvenile granulosa cell tumor (n = 8), Sertoli cell tumor (n = 1), Sertoli-Leydig cell tumor (n = 14), Leydig cell tumor (n = 2), steroid cell tumor, not otherwise specified (n = 2), sclerosing stromal tumor (n = 1), sex cord tumor with annular tubules (n = 2), and fibroma (n = 15).
  • Three uterine tumors resembling ovarian sex cord tumor were also studied.
  • Nonneoplastic ovaries, including 3 cases of pregnancy-related granulosa or Sertoli cell proliferation, were also included.
  • The normal ovarian stroma was diffusely positive, as were the 3 pregnancy-related proliferations.
  • All sex cord-stromal tumors except one were positive with CD56; staining ranged from focal to diffuse but was usually diffuse involving more than 50% of tumor cells.
  • CD56 immunoreactivity is almost universal in ovarian sex cord-stromal tumors of all the major morphological types and is of no value in distinguishing a sex cord-stromal and a neuroendocrine neoplasm.
  • Since CD56 is an extremely sensitive marker of ovarian sex cord-stromal tumors, it may be useful in the diagnosis of this group of neoplasms, especially in cases which are alpha inhibin or calretinin negative, and in distinguishing these from mimics which are CD56 negative.
  • [MeSH-major] Antigens, CD56 / metabolism. Biomarkers, Tumor / metabolism. Ovarian Neoplasms / metabolism. Sex Cord-Gonadal Stromal Tumors / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17581419.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD56; 0 / Biomarkers, Tumor
  •  go-up   go-down


58. Hoyer PB, Davis JR, Bedrnicek JB, Marion SL, Christian PJ, Barton JK, Brewer MA: Ovarian neoplasm development by 7,12-dimethylbenz[a]anthracene (DMBA) in a chemically-induced rat model of ovarian failure. Gynecol Oncol; 2009 Mar;112(3):610-5
Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian neoplasm development by 7,12-dimethylbenz[a]anthracene (DMBA) in a chemically-induced rat model of ovarian failure.
  • OBJECTIVES: The objectives were to determine the time course for ovarian failure in rats caused by 4-vinylcyclohexene diepoxide (VCD) and develop a model for ovarian cancer in which ovarian neoplasms were chemically induced in an animal that was follicle depleted, but retained residual ovarian tissue.
  • METHODS: Initially, female Fisher 344 rats were treated with VCD (to induce ovarian failure) or vehicle control (sesame oil).
  • Three or 6 months after treatment, ovaries were collected and processed for histological evaluation for confirmation of ovarian failure.
  • A further set of female rats was assigned to four groups exposed to combinations of vehicle control, VCD and/or DMBA (directly applied to the ovary) in a novel model for examining early stages of ovarian neoplasia.
  • RESULTS: Three and 6 months following VCD dosing there was a significant reduction of ovarian weight and follicle number.
  • Treatment with DMBA subsequent to VCD resulted in tumors in 42% of animals at 3 months and 57% at 5 months.
  • All neoplasms were classified Sertoli-Leydig cell tumors (SLCT).
  • No tumor occurred in animals treated with vehicle or DMBA alone.
  • DMBA induction of ovarian neoplasms was greater in those rats treated with VCD.
  • Whether this increase was due to tumor initiation by VCD or was the result of ovarian failure cannot be distinguished from these results.
  • This represents the only animal model to date for sex cord stromal tumors.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. VINYLCYCLOHEXENE DIOXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 2000 May;53(5):327-34 [10889812.001]
  • [Cites] J Bone Miner Res. 2008 Aug;23(8):1296-303 [18348702.001]
  • [Cites] Ecotoxicol Environ Saf. 2002 May;52(1):38-45 [12051806.001]
  • [Cites] Biol Reprod. 2002 Sep;67(3):718-24 [12193377.001]
  • [Cites] Mod Pathol. 2003 Jun;16(6):584-90 [12808064.001]
  • [Cites] Int J Gynecol Cancer. 2003 Jul-Aug;13(4):405-12 [12911715.001]
  • [Cites] Cancer Lett. 2004 Jul 16;210(2):129-37 [15183528.001]
  • [Cites] Biol Reprod. 2004 Jul;71(1):130-8 [14998904.001]
  • [Cites] Gan. 1967 Jun;58(3):253-66 [6081229.001]
  • [Cites] Int J Cancer. 1969 Jan 15;4(1):61-75 [4310334.001]
  • [Cites] Toxicol Appl Pharmacol. 1990 Sep 15;105(3):372-81 [2237912.001]
  • [Cites] Reprod Toxicol. 1994 Nov-Dec;8(6):509-14 [7881202.001]
  • [Cites] Toxicol Appl Pharmacol. 1996 Aug;139(2):394-401 [8806857.001]
  • [Cites] Cancer. 1998 Sep 1;83(5):965-70 [9731901.001]
  • [Cites] Reprod Toxicol. 1999 Jan-Feb;13(1):67-75 [10080302.001]
  • [Cites] Cancer Res. 2004 Nov 15;64(22):8177-83 [15548682.001]
  • [Cites] Carcinogenesis. 2005 May;26(5):951-7 [15695234.001]
  • [Cites] Cell Tissue Res. 2005 Oct;322(1):117-24 [15902502.001]
  • [Cites] Menopause. 2006 May-Jun;13(3):482-8 [16735946.001]
  • [Cites] Carcinogenesis. 2007 Jan;28(1):130-5 [16891317.001]
  • [Cites] Am J Surg Pathol. 2007 Feb;31(2):255-66 [17255771.001]
  • [Cites] Comp Med. 2007 Oct;57(5):443-9 [17974126.001]
  • [Cites] Biol Reprod. 2001 Jul;65(1):87-93 [11420227.001]
  • (PMID = 19150572.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / P30 ES006694-11A1; United States / NIA NIH HHS / AG / AG021948-03S1; United States / NIA NIH HHS / AG / AG021948-01; United States / NIA NIH HHS / AG / AG021948-05; United States / NIA NIH HHS / AG / AG021948-02; United States / NIA NIH HHS / AG / R01 AG021948-04; United States / NIA NIH HHS / AG / R01 AG021948-03S1; United States / NIEHS NIH HHS / ES / ES06694; United States / NIEHS NIH HHS / ES / P30 ES006694; United States / NIEHS NIH HHS / ES / ES006694-11A10001; United States / NCI NIH HHS / CA / CA119200-03; United States / NIEHS NIH HHS / ES / P30 ES006694-120001; United States / NIEHS NIH HHS / ES / P30 ES006694-12S1; United States / NCI NIH HHS / CA / R01 CA119200-03; United States / NIA NIH HHS / AG / R01 AG021948-02; United States / NIEHS NIH HHS / ES / ES006694-11A19006; United States / NIEHS NIH HHS / ES / P30 ES006694-12; United States / NCI NIH HHS / CA / R01 CA119200; United States / NIEHS NIH HHS / ES / ES006694-10S1; United States / NIA NIH HHS / AG / R01 AG021948-05; United States / NIEHS NIH HHS / ES / ES006694-120001; United States / NIA NIH HHS / AG / R01 AG021948; United States / NCI NIH HHS / CA / R01 CA119200-01A1; United States / NIEHS NIH HHS / ES / ES006694-130001; United States / NIA NIH HHS / AG / AG021948-03; United States / NIA NIH HHS / AG / R01 AG021948-03; United States / NIEHS NIH HHS / ES / P30 ES006694-11A19006; United States / NCI NIH HHS / CA / CA119200-01A1; United States / NIEHS NIH HHS / ES / P30 ES006694-130001; United States / NIEHS NIH HHS / ES / P30 ES006694-11A10001; United States / NIEHS NIH HHS / ES / P30 ES006694-13; United States / NIEHS NIH HHS / ES / ES006694-13; United States / NIA NIH HHS / AG / AG021948-04; United States / NCI NIH HHS / CA / CA119200; United States / NIA NIH HHS / AG / R01S AG021948; United States / NIEHS NIH HHS / ES / P30 ES006694-10S1; United States / NIEHS NIH HHS / ES / ES006694-10; United States / NIEHS NIH HHS / ES / ES006694-12S1; United States / NCI NIH HHS / CA / R01 CA119200-02; United States / NIEHS NIH HHS / ES / P30 ES006694-10; United States / NIA NIH HHS / AG / R01 AG021948-01; United States / NCI NIH HHS / CA / CA119200-02; United States / NIEHS NIH HHS / ES / ES006694-11A1; United States / NIEHS NIH HHS / ES / ES006694-12
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Cyclohexenes; 0 / Vinyl Compounds; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene; 596C064IG4 / 4-vinyl-1-cyclohexene dioxide
  • [Other-IDs] NLM/ NIHMS90041; NLM/ PMC2677070
  •  go-up   go-down


59. Teixeira RL, Rossini A, Paim NP: [Testicular tumors in childhood]. Rev Col Bras Cir; 2009 Feb;36(1):85-9
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Testicular tumors in childhood].
  • Testicular and paratesticular prepuberal tumors are rare.
  • They represent around 1% of the total of tumors of infancy.
  • They subdivide in 2 groups: germ cells tumors and non germ cells tumors, being able to occur in all the ages, and about 75% are malignant, and about 19% of these they present metastasis.
  • The tumors of germ cells tumors represent 60 75% of the tumors testiculars in infancy, having as main example the yolk sac tumor (65% of the neoplasms), followed for teratomas (14%); although some works to exist where teratoma, if presents as most common .The non germ cells tumors include the Leydig cell tumor and Sertoli cell tumor.
  • The Leydig cell tumor, are most frequent between the non germ cells tumors testicular.
  • This review article on epidemiology, diagnosis and treatment of to testicular and to paratesticular tumors in child.
  • [MeSH-minor] Child. Endodermal Sinus Tumor / pathology. Humans. Male. Teratoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20076873.001).
  • [ISSN] 1809-4546
  • [Journal-full-title] Revista do Colégio Brasileiro de Cirurgiões
  • [ISO-abbreviation] Rev Col Bras Cir
  • [Language] por
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Brazil
  • [Number-of-references] 35
  •  go-up   go-down


60. Azurmendi Arín I, Llarena Ibarguren R, Rodríguez JG, Olano Grasa I, Cantón Aller E, Pertusa Peña C: [Sertoli cell malignant tumor]. Arch Esp Urol; 2008 Sep;61(7):834-7
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Sertoli cell malignant tumor].
  • [Transliterated title] Tumor de células de Sertoli maligno.
  • OBJECTIVE: We report a new case of Sertoli cell testicular tumor with malignant characteristics.
  • METHODS: 77 year-old male patient, suffering a general wasting syndrome presenting with a left solid testicular mass with the diagnosis of malignant Sertoli cell tumor after orchyectomy, without local, regional or distant dissemination, and a benign outcome after 18 months of follow-up.
  • RESULTS: Sertoli cell tumor or androblastoma is classified as non-germ cell tumor derived from the stroma of the sexual cords.
  • There are three types depending on its cellular composition: calcified big cell, sclerotic cell, and the most frequent of all, the classic type.
  • CONCLUSIONS: Being the Sertoli cell testicular tumor rare, its malignant type is even rarer, accounting for not more than 10% of all.
  • [MeSH-major] Sertoli Cell Tumor. Testicular Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18972923.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


61. Lenhard M, Kuemper C, Ditsch N, Diebold J, Stieber P, Friese K, Burges A: Use of novel serum markers in clinical follow-up of Sertoli-Leydig cell tumours. Clin Chem Lab Med; 2007;45(5):657-61
Hazardous Substances Data Bank. ESTRADIOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of novel serum markers in clinical follow-up of Sertoli-Leydig cell tumours.
  • BACKGROUND: Sertoli-Leydig cell tumours of the ovary account for only 0.2% of malignant ovarian tumours.
  • Two-thirds of all patients become apparent due to the tumour's hormone production.
  • METHODS: A 41-year-old patient (gravida 4, para 4) presented with dyspnoea, enlarged abdominal girth and melaena.
  • Diagnostic imaging was suspicious for an ovarian cancer.
  • The standard tumour marker for ovarian cancer (CA 125) was elevated to 984 U/mL.
  • RESULTS: Surgical exploration of the abdomen revealed a mouldering tumour of both adnexes extending to the level of the navel.
  • The final histological report described a malignant sex-cord stroma tumour, a Sertoli-Leydig cell tumour, emanating from both ovaries.
  • Adjuvant chemotherapy and regional hyperthermia were performed due to the malignant potential and incomplete resection of the tumour.
  • CONCLUSIONS: Undifferentiated Sertoli-Leydig cell tumours show a poor clinical course.
  • As only two-thirds of patients with this rare disease present with elevated hormone levels, new markers deserve further investigation to offer more specific, individualised tumour monitoring.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17484630.001).
  • [ISSN] 1434-6621
  • [Journal-full-title] Clinical chemistry and laboratory medicine
  • [ISO-abbreviation] Clin. Chem. Lab. Med.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Keratin-19; 0 / antigen CYFRA21.1; 4TI98Z838E / Estradiol; 68238-35-7 / Keratins; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


62. Kline RC, Bazzett-Matabele LB: Adnexal masses and malignancies of importance to the colorectal surgeon. Clin Colon Rectal Surg; 2010 Jun;23(2):63-71

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this article, the authors review both benign and malignant ovarian masses, as the colorectal surgeon who encounters an adnexal mass at the time of surgery should be aware of the steps necessary for surgical staging and optimal tumor resection.Ovarian tumors-most of which are benign-are divided into three major categories, in order of frequency: epithelial, germ cell, and sex cord-stromal tumors.
  • Nonneoplastic conditions of the ovary that may present as adnexal masses include the following, according to World Health Organization (WHO) classification: pregnancy luteoma, hyperplasia of ovarian stroma, hyperthecosis, massive edema, solitary follicle cysts and corpus luteal cysts, multiple follicle cysts, and endometriosis.Epithelial ovarian tumors arise from the surface epithelium and can be benign or malignant.
  • Histologic types are serous, mucinous, endometrioid, clear cell, or Brenner.
  • Germ cell tumors are more likely to appear in females under 20 years, accounting for 70% of ovarian tumors in this age group.
  • Approximately 3% are malignant.
  • Teratomas are the most common germ cell tumors.
  • Malignancies, in addition to malignant teratomas, include dysgerminomas, endodermal sinus tumors, and embryonal carcinomas.
  • The more common sex cord-stromal tumors include granulosa stromal cell tumors, Sertoli-Leydig cell tumors, and gynandroblastomas.Surgical staging and optimal tumor resection are also addressed, with a focus on epithelial malignancies, as they are the most relevant to colorectal surgeons.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2001 Apr;81(1):77-81 [11277654.001]
  • [Cites] JAMA. 1983 Dec 9;250(22):3072-6 [6358558.001]
  • [Cites] Am J Obstet Gynecol. 2005 Jul;193(1):30-5 [16021055.001]
  • [Cites] Gynecol Oncol. 2006 Jan;100(1):185-91 [16216320.001]
  • [Cites] N Engl J Med. 2006 Jan 5;354(1):34-43 [16394300.001]
  • [Cites] Gynecol Oncol. 2006 Nov;103(2):383-90 [17005244.001]
  • [Cites] Obstet Gynecol. 2009 Apr;113(4):775-82 [19305319.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Int J Gynecol Pathol. 1990;9(4):343-51 [2246093.001]
  • [Cites] Curr Top Pathol. 1989;78:85-109 [2651026.001]
  • [Cites] Environ Health Perspect. 1987 Aug;73:15-25 [3665859.001]
  • [Cites] Obstet Gynecol. 1983 Apr;61(4):413-20 [6828269.001]
  • [Cites] Gynecol Oncol. 1989 Nov;35(2):139-44 [2680797.001]
  • [Cites] Obstet Gynecol. 1989 Dec;74(6):921-6 [2685680.001]
  • [Cites] J Clin Oncol. 1988 Jun;6(6):983-9 [3373267.001]
  • [Cites] Gynecol Oncol. 2002 Jul;86(1):34-7 [12079297.001]
  • (PMID = 21629623.001).
  • [ISSN] 1530-9681
  • [Journal-full-title] Clinics in colon and rectal surgery
  • [ISO-abbreviation] Clin Colon Rectal Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2967325
  • [Keywords] NOTNLM ; Adnexal masses / ovarian cancer / ovarian cysts
  •  go-up   go-down


63. Brown J, Sood AK, Deavers MT, Milojevic L, Gershenson DM: Patterns of metastasis in sex cord-stromal tumors of the ovary: can routine staging lymphadenectomy be omitted? Gynecol Oncol; 2009 Apr;113(1):86-90
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of metastasis in sex cord-stromal tumors of the ovary: can routine staging lymphadenectomy be omitted?
  • OBJECTIVE: Given the paucity of data regarding the patterns of metastasis from ovarian sex cord-stromal tumors (SCSTs), we sought to determine the risk of lymph node metastasis in patients with SCSTs.
  • METHODS: A retrospective chart review was performed after clinical and pathology databases were queried for ovarian SCST patients who were treated at our institution between 1985 and 2005.
  • RESULTS: We identified 262 patients with pathology-confirmed ovarian SCSTs; 5 had additional non-stromal histology and were excluded, leaving 257 evaluable patients.
  • Of these patients, 178 had adult granulosa cell tumors, 27 had juvenile granulosa cell tumors, 31 had Sertoli-Leydig cell tumors, 6 had sex cord tumors with annular tubules, 13 had mixed SCSTs, and 2 had SCSTs not otherwise specified.
  • Our evaluation showed that 111 patients underwent a complete or partial staging procedure; 75 had stage I disease, 11 had stage II disease, and 25 had stage III disease.
  • Of 117 patients whose disease eventually recurred, 6 patients (5.1%) had nodal metastases at the time of recurrence.
  • CONCLUSIONS: Lymph node metastasis in ovarian SCSTs is rare.
  • These findings suggest that lymphadenectomy may be omitted when staging patients with ovarian SCSTs.
  • [MeSH-major] Ovarian Neoplasms / pathology. Sex Cord-Gonadal Stromal Tumors / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Neoplasm Metastasis. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Retrospective Studies. Risk Factors

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19162310.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Martinez-Aguayo A, Rocha A, Rojas N, García C, Parra R, Lagos M, Valdivia L, Poggi H, Cattani A, Chilean Collaborative Testicular Adrenal Rest Tumor Study Group: Testicular adrenal rest tumors and Leydig and Sertoli cell function in boys with classical congenital adrenal hyperplasia. J Clin Endocrinol Metab; 2007 Dec;92(12):4583-9
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Testicular adrenal rest tumors and Leydig and Sertoli cell function in boys with classical congenital adrenal hyperplasia.
  • CONTEXT: Infertility observed in adult males with congenital adrenal hyperplasia (CAH) has been associated with testicular adrenal rest tumors (TART) that may originate during childhood.
  • OBJECTIVE: Our objective was to describe the prevalence of TART and Sertoli and Leydig cell function in a group of boys aged 2-10 yr with CAH and to compare prevalence with that of a control group.
  • METHODS: We studied 19 subjects in the CAH group and, as a control group, 13 boys from the community that did not have testicular diseases.
  • Inhibin B and anti-Müllerian hormone were used as Sertoli cell markers.
  • The ratio between basal testosterone levels and testosterone levels 72 h after beta-human chorionic gonadotropin (5000 U/m2) treatment [(T72- T0)/T0] was used to evaluate Leydig cell response.
  • [MeSH-major] Adrenal Hyperplasia, Congenital / physiopathology. Adrenal Rest Tumor / physiopathology. Leydig Cells / physiology. Sertoli Cells / physiology. Testicular Neoplasms / physiopathology


65. Chan JK, Zhang M, Kaleb V, Loizzi V, Benjamin J, Vasilev S, Osann K, Disaia PJ: Prognostic factors responsible for survival in sex cord stromal tumors of the ovary--a multivariate analysis. Gynecol Oncol; 2005 Jan;96(1):204-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors responsible for survival in sex cord stromal tumors of the ovary--a multivariate analysis.
  • OBJECTIVE: To evaluate prognostic factors that impacts the survival of women with sex cord stromal tumors of the ovary (SCST).
  • METHODS: Cases were identified from tumor registry databases at three academic institutions between 1975 and 2003.
  • RESULTS: Eighty-three women (median age: 49 years) with SCST of the ovary, including 73 with granulosa and 10 with Sertoli-Leydig cell tumors were identified.
  • The median and 5-year disease-specific survival of women with stage I-II vs. III-IV was 180 months and 85% compared to 58 months and 48%, respectively (P = 0.012).
  • Furthermore, age <50 (P = 0.003), premenopausal status (P = 0.013), tumor size < 10 cm (P = 0.003), lack of lymph node invasion (P < 0.0005), and absence of residual disease (P = 0.002) were all significant predictors for improved survival.
  • In multivariate analysis, age <50, smaller tumor size, and absence of residual disease remained as independent prognostic factors.
  • CONCLUSIONS: Age <50, smaller tumor size, and absence of residual disease are important predictors for improved survival in patients with SCST of the ovary.
  • [MeSH-major] Ovarian Neoplasms / mortality. Sex Cord-Gonadal Stromal Tumors / mortality
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Middle Aged. Multivariate Analysis. Neoplasm Staging. Prognosis. Proportional Hazards Models. Registries. Survival Rate

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15589602.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Misir A, Sur M: Sertoliform endometrioid carcinoma of the ovary: a potential diagnostic pitfall. Arch Pathol Lab Med; 2007 Jun;131(6):979-81
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sertoliform endometrioid carcinoma of the ovary: a potential diagnostic pitfall.
  • Sertoliform endometrioid carcinoma of the ovary (SEC) is an uncommon variant that bears histologic similarity to Sertoli and Sertoli-Leydig cell tumors (SLTs).
  • A number of histologic features can be used to distinguish the 2 entities, the most important ones being (1) the presence of areas with the usual pattern of endometrioid carcinoma, and (2) the presence of mucin at the apical borders of the tumor cells.
  • Based on the clinicopathologic behavior of this entity, SEC should be considered a well-differentiated carcinoma with relatively good prognosis if limited to the ovary.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Diagnostic Errors / prevention & control. Ovarian Neoplasms / pathology. Sertoli Cell Tumor / pathology
  • [MeSH-minor] Adenocarcinoma, Mucinous / diagnosis. Adult. Aged. Carcinoid Tumor / diagnosis. Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Krukenberg Tumor / diagnosis. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17550331.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Emerson RE, Wang M, Roth LM, Zheng W, Abdul-Karim FW, Liu F, Ulbright TM, Eble JN, Cheng L: Molecular genetic evidence supporting the neoplastic nature of the Leydig cell component of ovarian Sertoli-Leydig cell tumors. Int J Gynecol Pathol; 2007 Oct;26(4):368-74
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular genetic evidence supporting the neoplastic nature of the Leydig cell component of ovarian Sertoli-Leydig cell tumors.
  • Sertoli-Leydig cell tumors (SLCT) comprise less than 1% of ovarian tumors.
  • The nature of the Leydig cells has been a subject of controversy and it is unclear whether they are clonally related to the neoplasm or instead proliferate as a non-neoplastic response to the Sertoli-cell component.
  • Twelve ovarian SLCT were identified and hematoxylin and eosin and unstained sections were prepared from formalin-fixed, paraffin-embedded tissue blocks.
  • Tissue samples were microdissected from normal tissue, the Sertoli cell component, and the Leydig cell tumor component using the laser capture microdissection method.
  • LOH and/or nonrandom X-chromosome inactivation was observed in at least 1 of the 6 amplified loci in the Leydig cell component of 10 of the 12 tumors.
  • LOH and nonrandom X-chromosome inactivation patterns of the Sertoli cell component and Leydig cell component were compared.
  • Concordant allelic loss and/or matching X-chromosome inactivation patterns were observed in 8 (67%) of the 12 tumors.
  • In 7 of these tumors similar LOH or X-chromosome inactivation was observed at 1 site.
  • In 1 tumor similar LOH and/or X-chromosome inactivation was observed at 2 sites.
  • Three tumors had heterologous components.
  • The heterologous components similarly shared LOH/X-chromosome inactivation with the Sertoli cell components at 1 site in 1 case and 2 sites in 2 cases.
  • These data suggest that, at least in some cases, the Leydig cell component of SLCT is neoplastic rather than reactive in nature, and shares a common clonal origin with the coexisting Sertoli cell component.
  • Similarly, the heterologous components, when present, appear to share clonal origin with the Sertoli cell components.
  • [MeSH-major] Leydig Cells / pathology. Ovarian Neoplasms / genetics. Ovarian Neoplasms / pathology. Sertoli-Leydig Cell Tumor / genetics. Sertoli-Leydig Cell Tumor / pathology

  • Genetic Alliance. consumer health - Sertoli-leydig cell tumors.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17885485.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Zizi-Sermpetzoglou A, Petrakopoulou N, Tepelenis N, Savvaidou V, Manoloudaki K, Katsoulis M: Pure Sertoli cell tumor. a case report and review of the literature. Eur J Gynaecol Oncol; 2010;31(1):117-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pure Sertoli cell tumor. a case report and review of the literature.
  • Pure Sertoli cell tumor (SCT) is a rare sex cord tumor and a subtype of Sertoli-Leydig cell tumors according to the WHO Classification.
  • They lack a Leydig cell component and do not contain the immature neoplastic stroma found in the neoplasms of the Sertoli-Leydig cell category.
  • Sertoli cell tumors occur in women of reproductive age but a few can also occur in children.
  • The tumors are hormone functional in 40-60% of cases.
  • Microscopically they show always almost a tubular growth pattern, but they may also have other growth patterns which can be extensive, making the correct diagnosis difficult.
  • These histologic patterns may result in SCTs mimicking other ovarian tumors.
  • The immunohistochemical panel which usually includes EMA, inhibin, chromogranine, CD99 and calretinin is often helpful in establishing the diagnosis.
  • About 11% of Stage I tumors have worrisome histologic features that may portend an adverse outcome.
  • [MeSH-major] Ovarian Neoplasms / pathology. Sertoli Cell Tumor / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20349797.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 24
  •  go-up   go-down


69. Oliva E, Garcia-Miralles N, Vu Q, Young RH: CD10 expression in pure stromal and sex cord-stromal tumors of the ovary: an immunohistochemical analysis of 101 cases. Int J Gynecol Pathol; 2007 Oct;26(4):359-67
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD10 expression in pure stromal and sex cord-stromal tumors of the ovary: an immunohistochemical analysis of 101 cases.
  • CD10 has been recently advocated as a good immunohistochemical marker for endometrial stromal tumors.
  • Metastatic endometrial stromal tumors to the ovary and primary endometrioid stromal sarcomas may show overlapping histological features with pure stromal and sex cord-stromal tumors (SCSTs).
  • We investigated CD10 expression in a large series of pure stromal and SCSTs of the ovary to ascertain whether CD10 may aid in this differential diagnosis.
  • Archival material from 11 fibromas, 10 thecomas, 10 sclerosing stromal tumors (SSTs), 10 adult granulosa cell tumors (AGCTs), 4 luteinized AGCTs, 9 juvenile granulosa cell tumors (JGCTs), 9 Sertoli cell tumors, 9 Sertoli-Leydig cell tumors, 11 sex cord tumors with annular tubules, 10 steroid cell tumors (StCTs), and 8 fibrosarcomas of the ovary were immunostained for CD10.
  • CD10 was expressed in 7 of 10 thecomas (4 with 5%-75% and mostly 1+), 9 of 10 SSTs (7 with 5%-39% + cells, mostly 1+), 9 of 10 AGCTs (<5%-39%, four 1+, five 2+), 1 of 4 luteinized AGCTs (<5% and 1+), 8 of 9 JGCTs (mostly <5% to 39% and +1), 4 of 9 Sertoli cell tumors (either focal or >75% with variable intensity), 4 of 9 Sertoli-Leydig cell tumors (mostly <10% with variable staining), with the Leydig cells being positive in only 1 tumor (1+ and <5%), and 7 of 10 StCTs (4 tumors with more than 75% + cells, from 1+ to 3+).
  • All fibromas, all but 1 fibrosarcoma (<5% and 1+), and all sex cord tumors with annular tubules were CD10 negative.
  • CD10 expression was frequently seen in StCTs, SSTs, and thecomas of the ovary, although the latter 2 categories usually showed only faint immunoreactivity.
  • In conclusion the frequency and intensity of CD10 immunoreactivity in pure stromal and sex cord-stromal ovarian tumors are low and contrast with the typical strong and diffuse immunostaining seen in endometrial stromal tumors; however, faint CD10 positivity is consistent with the diagnosis of ovarian SCST.
  • Steroid cell tumors are often positive for CD10, but these tumors do not pose problems in differential diagnosis with endometrial stromal tumors.
  • CD10 may play a useful role in aiding the differential between endometrial stromal tumors in the ovary and SCST and stromal tumors.
  • [MeSH-major] Neprilysin / biosynthesis. Ovarian Neoplasms / metabolism. Sex Cord-Gonadal Stromal Tumors / metabolism
  • [MeSH-minor] Biomarkers, Tumor / analysis. Diagnosis, Differential. Endometrial Stromal Tumors / pathology. Female. Humans. Immunohistochemistry. Pregnancy. Pregnancy Complications, Neoplastic / metabolism. Pregnancy Complications, Neoplastic / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17885484.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


70. Devouassoux-Shisheboran M, Deschildre C, Mauduit C, Berger G, Mejean-Lebreton F, Bouvier R, Droz JP, Fénichel P, Benahmed M: Expression of galectin-3 in gonads and gonadal sex cord stromal and germ cell tumors. Oncol Rep; 2006 Aug;16(2):335-40
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of galectin-3 in gonads and gonadal sex cord stromal and germ cell tumors.
  • Galectin-3, a beta-galactoside-binding lectin, has been implicated in many human malignancies, but has seldom been studied in human gonads and gonadal tumors.
  • The aim of our study was to investigate galectin-3 mRNA and protein expression in normal ovaries and testes as well as in a variety of 51 gonadal sex cord stromal and germ cell tumors, and two testicular seminomatous and non-seminomatous cell lines, using either real-time PCR or immunohistochemistry.
  • In human testes, galectin-3 is specifically expressed in mature Sertoli cells and Leydig cells, and is absent from fetal and pre-pubertal testes, suggesting a hormone-dependence of this gene.
  • In human ovaries, galectin-3 is absent from granulosa cells, as well as from granulosa cell and Sertoli-Leydig cell tumors, and is not a useful marker in distinguishing granulosa cell from Sertoli-Leydig cell tumors.
  • In testicular tumorigenesis, galectin-3 has a dual function according to the histological type of tumors and their hormone dependency.
  • In malignant testicular Sertoli cell tumors, the expression of galectin-3 is down-regulated while, in benign Leydig cell tumors, this expression is maintained, indicating the possible implication of this gene in the development of more aggressive testicular sex cord stromal tumors.
  • In contrast to sex cord stromal tumors, galectin-3 expression is up-regulated in testicular germ cell tumors.
  • By real-time PCR, we demonstrated a significant elevation of the galectin-3 mRNA level in non-seminomatous testicular germ cell tumors and cell line as compared to normal testes and seminomas (p=0.0432 and p=0.0247, respectively), indicating the possible role of this gene in the non-seminomatous differentiation of germ cell tumors.
  • [MeSH-major] Biomarkers, Tumor / analysis. Galectin 3 / analysis. Sertoli Cell Tumor / diagnosis. Sex Cord-Gonadal Stromal Tumors / diagnosis. Testicular Neoplasms / diagnosis
  • [MeSH-minor] Female. Humans. Immunohistochemistry. Male. Ovarian Neoplasms / chemistry. Ovarian Neoplasms / diagnosis. Ovary / chemistry. RNA, Messenger / analysis. Receptors, Androgen / analysis. Reverse Transcriptase Polymerase Chain Reaction. Sertoli Cells / chemistry. Testis / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16820912.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Galectin 3; 0 / RNA, Messenger; 0 / Receptors, Androgen
  •  go-up   go-down


71. Schneider DT, Calaminus G, Harms D, Göbel U, German Maligne Keimzelltumoren Study Group: Ovarian sex cord-stromal tumors in children and adolescents. J Reprod Med; 2005 Jun;50(6):439-46
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian sex cord-stromal tumors in children and adolescents.
  • Ovarian sex cord-stromal tumors (OSCSTs) are a heterogeneous group of tumors that develop from the gonadal non-germ-cell component.
  • Despite recent advances in the clinical and histopathologic diagnosis of OSCSTs, a high degree of uncertainty remains with regard to adequate therapy, particularly in patients presenting with microscopic or macroscopic tumor spread.
  • In addition, we summarize the data from our clinical, histopathologic and genetic analyses of patients that were prospectively reported to the German MAKEI protocols for treatment of nontesticular malignant germ cell tumors.
  • Among these patients, juvenile granulosa cell tumors (JGCTs) constitute the most frequent histologic subtype, followed by Sertoli-Leydig cell tumors (SLCTs) and sclerosing stromal tumors.
  • In addition, prognosis correlates with tumor stage according to the International Federation of Obstetrics and Gynecology.
  • Nevertheless, we observed a favorable response to cisplatin-based chemotherapy in the majority of stage II and III tumors.
  • Genetic analysis of 27 tumors available for comparative genomic hybridization analysis revealed normal profiles in the majority of tumors and whole chromosomal gain, such as a gain of 12 in single tumors, with no consistent pattern with regard to histology or clinical outcome.
  • This analysis confirmed that most OSCSTs present at a low tumor stage and that prognosis in these patients is excellent.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ovarian Neoplasms / therapy. Sex Cord-Gonadal Stromal Tumors / therapy
  • [MeSH-minor] Adolescent. Chemotherapy, Adjuvant. Child. Cisplatin / therapeutic use. Combined Modality Therapy. Disease-Free Survival. Female. Germany. Humans. Neoplasm Staging. Prognosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16050568.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin
  • [Number-of-references] 27
  •  go-up   go-down


72. Young RH: Testicular tumors--some new and a few perennial problems. Arch Pathol Lab Med; 2008 Apr;132(4):548-64
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Testicular tumors--some new and a few perennial problems.
  • The histopathology of testicular tumors is presented, emphasizing new, unusual, or underemphasized aspects.
  • Within the category of seminoma of the usual type, the recent literature has drawn attention to the presence in occasional tumors of solid or hollow tubules or spaces of varying sizes and shape that may result in cribriform or microcystic patterns, causing potential confusion with other neoplasms, most notably Sertoli cell tumor or yolk sac tumor.
  • Although regions of typical neoplasia and awareness of this phenomenon usually will be diagnostic, immunohistochemistry may play a role in excluding Sertoli cell tumor or yolk sac tumor.
  • Although immunohistochemistry can play an undoubted helpful role in this and selected other areas of testicular tumor evaluation, careful evaluation of the gross and routine microscopic features will solve the vast majority of diagnostic problems.
  • Spermatocytic seminoma remains a crucial pitfall in diagnosis, and the pathologist must always be alert to the possible diagnosis when looking at a seminomatous neoplasm, particularly in an older patient, although about one third of these tumors occur in the usual seminoma age range.
  • The enigmatic and picturesque tumor, polyembryoma, which virtually never occurs in pure form but may be a confusing component of a variety of mixed germ cell tumors, is discussed and illustrated.
  • The phenomenon of burnt-out germ cell neoplasia is also briefly noted and an excellent recent contribution is referred to.
  • Within the sex cord-stromal family of neoplasms, recent contributions and elaborations of unusual morphologic features of Leydig cell tumors and Sertoli cell tumors are presented.
  • Within the Leydig cell family, cyst formation, adipose metaplasia, calcification or ossification, and spindle cell patterns may be particularly confusing, and in the Sertoli cell family, a great array of patterns caused by differing admixtures of tubular, solid, and stromal components occur.
  • The peculiar lesion, intratubular large cell hyalinizing Sertoli cell tumor, of young boys with Peutz-Jeghers syndrome, is briefly discussed.
  • Some of the problems in the family of hematopoietic neoplasms are reviewed, these processes posing diverse problems in differential diagnosis and their correct recognition having crucial therapeutic implications.
  • Although secondary tumors to the testis have not received the same attention in the literature as the similar phenomenon in the female gonad, remarkable examples of testicular spread of diverse neoplasms, usually carcinoma but rarely melanoma, are seen, and the pathologist should be alert to this possibility, particularly when examining an unusual morphology in an older patient.
  • Finally, a few comments are made on the common paratesticular neoplasm, the adenomatoid tumor, highlighting its varied patterns and recent description of some of the issues that may arise when they undergo total or subtotal infarction.
  • [MeSH-major] Pathology / education. Testicular Neoplasms / diagnosis. Testicular Neoplasms / pathology
  • [MeSH-minor] Carcinoma, Embryonal / diagnosis. Carcinoma, Embryonal / pathology. Diagnosis, Differential. Endodermal Sinus Tumor / diagnosis. Endodermal Sinus Tumor / pathology. Humans. Male. Neoplasms, Germ Cell and Embryonal / diagnosis. Neoplasms, Germ Cell and Embryonal / pathology. Seminoma / diagnosis. Seminoma / pathology. Teratoma / diagnosis. Teratoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18384207.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 54
  •  go-up   go-down


73. Nicoletto MO, Caltarossa E, Donach M, Nardelli GB, Parenti A, Ambrosini A: Sertoli cell tumor: a rare case in an elderly patient. Eur J Gynaecol Oncol; 2006;27(1):86-7
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sertoli cell tumor: a rare case in an elderly patient.
  • Sertoli-Leydig cell tumors constitute < 1% of ovarian tumors, mostly in young women with virilization; however, not all present endocrine manifestations.
  • The pathologic diagnosis was poorly-differentiated sex cord-stromal tumor with Sertoli cells.
  • At 12-month follow-up the patient showed no evidence of disease.
  • [MeSH-major] Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery. Sertoli Cell Tumor / pathology. Sertoli Cell Tumor / surgery
  • [MeSH-minor] Age Factors. Aged. Biopsy, Needle. Female. Follow-Up Studies. Humans. Hysterectomy / methods. Immunohistochemistry. Neoplasm Staging. Ovariectomy / methods. Rare Diseases. Risk Assessment. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16550978.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 13
  •  go-up   go-down


74. Soini Y, Talvensaari-Mattila A: Expression of claudins 1, 4, 5, and 7 in ovarian tumors of diverse types. Int J Gynecol Pathol; 2006 Oct;25(4):330-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of claudins 1, 4, 5, and 7 in ovarian tumors of diverse types.
  • In this study, 60 different types of ovarian lesions, mainly consisting of ovarian neoplasms, were studied for the expression of claudins 1, 4, 5, and 7.
  • Strong expression of claudins 1, 4, and 7 was seen in benign and malignant epithelial ovarian tumors.
  • Expression of claudin 5, reported to be mainly present in endothelial cells, was seen in ovarian epithelial tumors, but with a significantly lower frequency than claudins 1, 4, and 7.
  • On the contrary, sex-cord stromal tumors and cysts, such as fibromas/thecomas, Sertoli-Leydig cell tumors, granulosa cell tumors, and follicular and luteinized cysts were mainly negative for claudins 1, 4, 5, and 7.
  • Interestingly, adenomatoid tumors did not express claudin 5, which is in agreement with their non-endothelial nature.
  • The results show that claudins 1, 4, and 7 are mainly expressed in ovarian epithelial tumors and can thus be used to indicate epithelial differentiation in them.
  • However, this claudin can be used to differentiate adenomatoid tumors from vascular lesions.
  • No significant difference was seen between epithelial benign and malignant lesions, except for claudin 5, which seemed stronger in malignant epithelial tumors.
  • [MeSH-major] Membrane Proteins / analysis. Ovarian Neoplasms / chemistry
  • [MeSH-minor] Adenomatoid Tumor / chemistry. Brenner Tumor / chemistry. Carcinoma / chemistry. Claudin-1. Claudin-4. Claudin-5. Claudins. Dysgerminoma / chemistry. Female. Humans. Immunohistochemistry. Krukenberg Tumor / chemistry. Ovarian Cysts. Sex Cord-Gonadal Stromal Tumors / chemistry. Teratoma / chemistry

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16990707.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CLDN1 protein, human; 0 / CLDN4 protein, human; 0 / CLDN5 protein, human; 0 / CLDN7 protein, human; 0 / Claudin-1; 0 / Claudin-4; 0 / Claudin-5; 0 / Claudins; 0 / Membrane Proteins
  •  go-up   go-down


75. Tandon R, Goel P, Saha PK, Takkar N, Punia RP: A rare ovarian tumor - Sertoli-Leydig cell tumor with heterologous element. MedGenMed; 2007;9(4):44
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare ovarian tumor - Sertoli-Leydig cell tumor with heterologous element.
  • [MeSH-major] Neoplasm Invasiveness / pathology. Ovarian Neoplasms / pathology. Sertoli-Leydig Cell Tumor / pathology
  • [MeSH-minor] Adult. Biopsy, Needle. Female. Follow-Up Studies. Humans. Immunohistochemistry. Neoplasm Staging. Ovariectomy / methods. Rare Diseases. Risk Assessment. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Reprod Med. 2001 May;46(5):493-6 [11396379.001]
  • [Cites] J Pediatr Adolesc Gynecol. 2004 Feb;17(1):49-52 [15010040.001]
  • [Cites] Indian J Pathol Microbiol. 2003 Jan;46(1):91-3 [15027740.001]
  • [Cites] Am J Obstet Gynecol. 1976 Jun 1;125(3):402-11 [1275030.001]
  • [Cites] Arch Gynecol Obstet. 2001 Jan;264(4):206-8 [11205710.001]
  • [Cites] Am J Surg Pathol. 1985 Aug;9(8):543-69 [3911780.001]
  • [Cites] Obstet Gynecol. 1987 Nov;70(5):765-9 [3658288.001]
  • [Cites] Obstet Gynecol. 1996 Apr;87(4):527-31 [8602303.001]
  • [Cites] Am J Surg Pathol. 1984 Jun;8(6):405-18 [6731664.001]
  • (PMID = 18311394.001).
  • [ISSN] 1531-0132
  • [Journal-full-title] MedGenMed : Medscape general medicine
  • [ISO-abbreviation] MedGenMed
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2234306
  •  go-up   go-down


76. Shi JL, Guo LN, Lang JH: [Advances in Sertoli-Leydig cell tumour of the ovary]. Zhonghua Bing Li Xue Za Zhi; 2008 Sep;37(9):631-3
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Advances in Sertoli-Leydig cell tumour of the ovary].
  • [MeSH-major] Ovarian Neoplasms / pathology. Ovary / pathology. Proto-Oncogene Proteins / metabolism. Proto-Oncogenes / immunology. Sertoli-Leydig Cell Tumor / pathology. ras Proteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19094590.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] Lectures
  • [Publication-country] China
  • [Chemical-registry-number] 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


77. Kawakita M: [Testicular neoplasms (germ cell tumors, Leydig cell tumor, Sertoli cell tumor)]. Nihon Rinsho; 2006 Jun 28;Suppl 2:291-5
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Testicular neoplasms (germ cell tumors, Leydig cell tumor, Sertoli cell tumor)].
  • [MeSH-major] Leydig Cell Tumor. Neoplasms, Germ Cell and Embryonal. Sertoli Cell Tumor. Testicular Neoplasms
  • [MeSH-minor] Humans. Lymph Node Excision. Male. Neoplasm Staging. Orchiectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16817406.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 16
  •  go-up   go-down


78. Vissiennon T, Schmidt T, Schneider E, Hildebrand M: Sertoli Leydig cell tumour in a bitch, 10 years after spaying. A case report. Tierarztl Prax Ausg K Kleintiere Heimtiere; 2010;38(6):399-402

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sertoli Leydig cell tumour in a bitch, 10 years after spaying. A case report.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22212753.001).
  • [ISSN] 1434-1239
  • [Journal-full-title] Tierärztliche Praxis. Ausgabe K, Kleintiere/Heimtiere
  • [ISO-abbreviation] Tierarztl Prax Ausg K Kleintiere Heimtiere
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


79. de Oliveira Franzin CM, Kraft ML, Faundes D, Zeferino LC, Alvarenga M, Marussi EF: Detection of ovarian Sertoli-Leydig cell tumors exclusively by color Doppler sonography. J Ultrasound Med; 2006 Oct;25(10):1327-30
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of ovarian Sertoli-Leydig cell tumors exclusively by color Doppler sonography.
  • [MeSH-major] Ovarian Neoplasms / ultrasonography. Sertoli-Leydig Cell Tumor / ultrasonography

  • Genetic Alliance. consumer health - Sertoli-leydig cell tumors.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16998106.001).
  • [ISSN] 0278-4297
  • [Journal-full-title] Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  • [ISO-abbreviation] J Ultrasound Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement